Deprecated (16384): The ArrayAccess methods will be removed in 4.0.0.Use getParam(), getData() and getQuery() instead. - /home/brlfuser/public_html/src/Controller/ArtileDetailController.php, line: 73
 You can disable deprecation warnings by setting `Error.errorLevel` to `E_ALL & ~E_USER_DEPRECATED` in your config/app.php. [CORE/src/Core/functions.php, line 311]
Code Context


        trigger_error($message, E_USER_DEPRECATED);

    }
$message = 'The ArrayAccess methods will be removed in 4.0.0.Use getParam(), getData() and getQuery() instead. - /home/brlfuser/public_html/src/Controller/ArtileDetailController.php, line: 73
 You can disable deprecation warnings by setting `Error.errorLevel` to `E_ALL & ~E_USER_DEPRECATED` in your config/app.php.'
$stackFrame = (int) 1
$trace = [
	(int) 0 => [
		'file' => '/home/brlfuser/public_html/vendor/cakephp/cakephp/src/Http/ServerRequest.php',
		'line' => (int) 2421,
		'function' => 'deprecationWarning',
		'args' => [
			(int) 0 => 'The ArrayAccess methods will be removed in 4.0.0.Use getParam(), getData() and getQuery() instead.'
		]
	],
	(int) 1 => [
		'file' => '/home/brlfuser/public_html/src/Controller/ArtileDetailController.php',
		'line' => (int) 73,
		'function' => 'offsetGet',
		'class' => 'Cake\Http\ServerRequest',
		'object' => object(Cake\Http\ServerRequest) {},
		'type' => '->',
		'args' => [
			(int) 0 => 'catslug'
		]
	],
	(int) 2 => [
		'file' => '/home/brlfuser/public_html/vendor/cakephp/cakephp/src/Controller/Controller.php',
		'line' => (int) 610,
		'function' => 'printArticle',
		'class' => 'App\Controller\ArtileDetailController',
		'object' => object(App\Controller\ArtileDetailController) {},
		'type' => '->',
		'args' => []
	],
	(int) 3 => [
		'file' => '/home/brlfuser/public_html/vendor/cakephp/cakephp/src/Http/ActionDispatcher.php',
		'line' => (int) 120,
		'function' => 'invokeAction',
		'class' => 'Cake\Controller\Controller',
		'object' => object(App\Controller\ArtileDetailController) {},
		'type' => '->',
		'args' => []
	],
	(int) 4 => [
		'file' => '/home/brlfuser/public_html/vendor/cakephp/cakephp/src/Http/ActionDispatcher.php',
		'line' => (int) 94,
		'function' => '_invoke',
		'class' => 'Cake\Http\ActionDispatcher',
		'object' => object(Cake\Http\ActionDispatcher) {},
		'type' => '->',
		'args' => [
			(int) 0 => object(App\Controller\ArtileDetailController) {}
		]
	],
	(int) 5 => [
		'file' => '/home/brlfuser/public_html/vendor/cakephp/cakephp/src/Http/BaseApplication.php',
		'line' => (int) 235,
		'function' => 'dispatch',
		'class' => 'Cake\Http\ActionDispatcher',
		'object' => object(Cake\Http\ActionDispatcher) {},
		'type' => '->',
		'args' => [
			(int) 0 => object(Cake\Http\ServerRequest) {},
			(int) 1 => object(Cake\Http\Response) {}
		]
	],
	(int) 6 => [
		'file' => '/home/brlfuser/public_html/vendor/cakephp/cakephp/src/Http/Runner.php',
		'line' => (int) 65,
		'function' => '__invoke',
		'class' => 'Cake\Http\BaseApplication',
		'object' => object(App\Application) {},
		'type' => '->',
		'args' => [
			(int) 0 => object(Cake\Http\ServerRequest) {},
			(int) 1 => object(Cake\Http\Response) {},
			(int) 2 => object(Cake\Http\Runner) {}
		]
	],
	(int) 7 => [
		'file' => '/home/brlfuser/public_html/vendor/cakephp/cakephp/src/Routing/Middleware/RoutingMiddleware.php',
		'line' => (int) 162,
		'function' => '__invoke',
		'class' => 'Cake\Http\Runner',
		'object' => object(Cake\Http\Runner) {},
		'type' => '->',
		'args' => [
			(int) 0 => object(Cake\Http\ServerRequest) {},
			(int) 1 => object(Cake\Http\Response) {}
		]
	],
	(int) 8 => [
		'file' => '/home/brlfuser/public_html/vendor/cakephp/cakephp/src/Http/Runner.php',
		'line' => (int) 65,
		'function' => '__invoke',
		'class' => 'Cake\Routing\Middleware\RoutingMiddleware',
		'object' => object(Cake\Routing\Middleware\RoutingMiddleware) {},
		'type' => '->',
		'args' => [
			(int) 0 => object(Cake\Http\ServerRequest) {},
			(int) 1 => object(Cake\Http\Response) {},
			(int) 2 => object(Cake\Http\Runner) {}
		]
	],
	(int) 9 => [
		'file' => '/home/brlfuser/public_html/vendor/cakephp/cakephp/src/Routing/Middleware/AssetMiddleware.php',
		'line' => (int) 88,
		'function' => '__invoke',
		'class' => 'Cake\Http\Runner',
		'object' => object(Cake\Http\Runner) {},
		'type' => '->',
		'args' => [
			(int) 0 => object(Cake\Http\ServerRequest) {},
			(int) 1 => object(Cake\Http\Response) {}
		]
	],
	(int) 10 => [
		'file' => '/home/brlfuser/public_html/vendor/cakephp/cakephp/src/Http/Runner.php',
		'line' => (int) 65,
		'function' => '__invoke',
		'class' => 'Cake\Routing\Middleware\AssetMiddleware',
		'object' => object(Cake\Routing\Middleware\AssetMiddleware) {},
		'type' => '->',
		'args' => [
			(int) 0 => object(Cake\Http\ServerRequest) {},
			(int) 1 => object(Cake\Http\Response) {},
			(int) 2 => object(Cake\Http\Runner) {}
		]
	],
	(int) 11 => [
		'file' => '/home/brlfuser/public_html/vendor/cakephp/cakephp/src/Error/Middleware/ErrorHandlerMiddleware.php',
		'line' => (int) 96,
		'function' => '__invoke',
		'class' => 'Cake\Http\Runner',
		'object' => object(Cake\Http\Runner) {},
		'type' => '->',
		'args' => [
			(int) 0 => object(Cake\Http\ServerRequest) {},
			(int) 1 => object(Cake\Http\Response) {}
		]
	],
	(int) 12 => [
		'file' => '/home/brlfuser/public_html/vendor/cakephp/cakephp/src/Http/Runner.php',
		'line' => (int) 65,
		'function' => '__invoke',
		'class' => 'Cake\Error\Middleware\ErrorHandlerMiddleware',
		'object' => object(Cake\Error\Middleware\ErrorHandlerMiddleware) {},
		'type' => '->',
		'args' => [
			(int) 0 => object(Cake\Http\ServerRequest) {},
			(int) 1 => object(Cake\Http\Response) {},
			(int) 2 => object(Cake\Http\Runner) {}
		]
	],
	(int) 13 => [
		'file' => '/home/brlfuser/public_html/vendor/cakephp/cakephp/src/Http/Runner.php',
		'line' => (int) 51,
		'function' => '__invoke',
		'class' => 'Cake\Http\Runner',
		'object' => object(Cake\Http\Runner) {},
		'type' => '->',
		'args' => [
			(int) 0 => object(Cake\Http\ServerRequest) {},
			(int) 1 => object(Cake\Http\Response) {}
		]
	],
	(int) 14 => [
		'file' => '/home/brlfuser/public_html/vendor/cakephp/cakephp/src/Http/Server.php',
		'line' => (int) 98,
		'function' => 'run',
		'class' => 'Cake\Http\Runner',
		'object' => object(Cake\Http\Runner) {},
		'type' => '->',
		'args' => [
			(int) 0 => object(Cake\Http\MiddlewareQueue) {},
			(int) 1 => object(Cake\Http\ServerRequest) {},
			(int) 2 => object(Cake\Http\Response) {}
		]
	],
	(int) 15 => [
		'file' => '/home/brlfuser/public_html/webroot/index.php',
		'line' => (int) 39,
		'function' => 'run',
		'class' => 'Cake\Http\Server',
		'object' => object(Cake\Http\Server) {},
		'type' => '->',
		'args' => []
	]
]
$frame = [
	'file' => '/home/brlfuser/public_html/src/Controller/ArtileDetailController.php',
	'line' => (int) 73,
	'function' => 'offsetGet',
	'class' => 'Cake\Http\ServerRequest',
	'object' => object(Cake\Http\ServerRequest) {
		trustProxy => false
		[protected] params => [
			[maximum depth reached]
		]
		[protected] data => [[maximum depth reached]]
		[protected] query => [[maximum depth reached]]
		[protected] cookies => [
			[maximum depth reached]
		]
		[protected] _environment => [
			[maximum depth reached]
		]
		[protected] url => 'latest-news-updates/novartis-patent-ruling-a-victory-in-battle-for-affordable-medicines-sarah-boseley-20308/print'
		[protected] base => ''
		[protected] webroot => '/'
		[protected] here => '/latest-news-updates/novartis-patent-ruling-a-victory-in-battle-for-affordable-medicines-sarah-boseley-20308/print'
		[protected] trustedProxies => [[maximum depth reached]]
		[protected] _input => null
		[protected] _detectors => [
			[maximum depth reached]
		]
		[protected] _detectorCache => [
			[maximum depth reached]
		]
		[protected] stream => object(Zend\Diactoros\PhpInputStream) {}
		[protected] uri => object(Zend\Diactoros\Uri) {}
		[protected] session => object(Cake\Http\Session) {}
		[protected] attributes => [[maximum depth reached]]
		[protected] emulatedAttributes => [
			[maximum depth reached]
		]
		[protected] uploadedFiles => [[maximum depth reached]]
		[protected] protocol => null
		[protected] requestTarget => null
		[private] deprecatedProperties => [
			[maximum depth reached]
		]
	},
	'type' => '->',
	'args' => [
		(int) 0 => 'catslug'
	]
]
deprecationWarning - CORE/src/Core/functions.php, line 311
Cake\Http\ServerRequest::offsetGet() - CORE/src/Http/ServerRequest.php, line 2421
App\Controller\ArtileDetailController::printArticle() - APP/Controller/ArtileDetailController.php, line 73
Cake\Controller\Controller::invokeAction() - CORE/src/Controller/Controller.php, line 610
Cake\Http\ActionDispatcher::_invoke() - CORE/src/Http/ActionDispatcher.php, line 120
Cake\Http\ActionDispatcher::dispatch() - CORE/src/Http/ActionDispatcher.php, line 94
Cake\Http\BaseApplication::__invoke() - CORE/src/Http/BaseApplication.php, line 235
Cake\Http\Runner::__invoke() - CORE/src/Http/Runner.php, line 65
Cake\Routing\Middleware\RoutingMiddleware::__invoke() - CORE/src/Routing/Middleware/RoutingMiddleware.php, line 162
Cake\Http\Runner::__invoke() - CORE/src/Http/Runner.php, line 65
Cake\Routing\Middleware\AssetMiddleware::__invoke() - CORE/src/Routing/Middleware/AssetMiddleware.php, line 88
Cake\Http\Runner::__invoke() - CORE/src/Http/Runner.php, line 65
Cake\Error\Middleware\ErrorHandlerMiddleware::__invoke() - CORE/src/Error/Middleware/ErrorHandlerMiddleware.php, line 96
Cake\Http\Runner::__invoke() - CORE/src/Http/Runner.php, line 65
Cake\Http\Runner::run() - CORE/src/Http/Runner.php, line 51
Cake\Http\Server::run() - CORE/src/Http/Server.php, line 98

Deprecated (16384): The ArrayAccess methods will be removed in 4.0.0.Use getParam(), getData() and getQuery() instead. - /home/brlfuser/public_html/src/Controller/ArtileDetailController.php, line: 74
 You can disable deprecation warnings by setting `Error.errorLevel` to `E_ALL & ~E_USER_DEPRECATED` in your config/app.php. [CORE/src/Core/functions.php, line 311]
Code Context


        trigger_error($message, E_USER_DEPRECATED);

    }
$message = 'The ArrayAccess methods will be removed in 4.0.0.Use getParam(), getData() and getQuery() instead. - /home/brlfuser/public_html/src/Controller/ArtileDetailController.php, line: 74
 You can disable deprecation warnings by setting `Error.errorLevel` to `E_ALL & ~E_USER_DEPRECATED` in your config/app.php.'
$stackFrame = (int) 1
$trace = [
	(int) 0 => [
		'file' => '/home/brlfuser/public_html/vendor/cakephp/cakephp/src/Http/ServerRequest.php',
		'line' => (int) 2421,
		'function' => 'deprecationWarning',
		'args' => [
			(int) 0 => 'The ArrayAccess methods will be removed in 4.0.0.Use getParam(), getData() and getQuery() instead.'
		]
	],
	(int) 1 => [
		'file' => '/home/brlfuser/public_html/src/Controller/ArtileDetailController.php',
		'line' => (int) 74,
		'function' => 'offsetGet',
		'class' => 'Cake\Http\ServerRequest',
		'object' => object(Cake\Http\ServerRequest) {},
		'type' => '->',
		'args' => [
			(int) 0 => 'artileslug'
		]
	],
	(int) 2 => [
		'file' => '/home/brlfuser/public_html/vendor/cakephp/cakephp/src/Controller/Controller.php',
		'line' => (int) 610,
		'function' => 'printArticle',
		'class' => 'App\Controller\ArtileDetailController',
		'object' => object(App\Controller\ArtileDetailController) {},
		'type' => '->',
		'args' => []
	],
	(int) 3 => [
		'file' => '/home/brlfuser/public_html/vendor/cakephp/cakephp/src/Http/ActionDispatcher.php',
		'line' => (int) 120,
		'function' => 'invokeAction',
		'class' => 'Cake\Controller\Controller',
		'object' => object(App\Controller\ArtileDetailController) {},
		'type' => '->',
		'args' => []
	],
	(int) 4 => [
		'file' => '/home/brlfuser/public_html/vendor/cakephp/cakephp/src/Http/ActionDispatcher.php',
		'line' => (int) 94,
		'function' => '_invoke',
		'class' => 'Cake\Http\ActionDispatcher',
		'object' => object(Cake\Http\ActionDispatcher) {},
		'type' => '->',
		'args' => [
			(int) 0 => object(App\Controller\ArtileDetailController) {}
		]
	],
	(int) 5 => [
		'file' => '/home/brlfuser/public_html/vendor/cakephp/cakephp/src/Http/BaseApplication.php',
		'line' => (int) 235,
		'function' => 'dispatch',
		'class' => 'Cake\Http\ActionDispatcher',
		'object' => object(Cake\Http\ActionDispatcher) {},
		'type' => '->',
		'args' => [
			(int) 0 => object(Cake\Http\ServerRequest) {},
			(int) 1 => object(Cake\Http\Response) {}
		]
	],
	(int) 6 => [
		'file' => '/home/brlfuser/public_html/vendor/cakephp/cakephp/src/Http/Runner.php',
		'line' => (int) 65,
		'function' => '__invoke',
		'class' => 'Cake\Http\BaseApplication',
		'object' => object(App\Application) {},
		'type' => '->',
		'args' => [
			(int) 0 => object(Cake\Http\ServerRequest) {},
			(int) 1 => object(Cake\Http\Response) {},
			(int) 2 => object(Cake\Http\Runner) {}
		]
	],
	(int) 7 => [
		'file' => '/home/brlfuser/public_html/vendor/cakephp/cakephp/src/Routing/Middleware/RoutingMiddleware.php',
		'line' => (int) 162,
		'function' => '__invoke',
		'class' => 'Cake\Http\Runner',
		'object' => object(Cake\Http\Runner) {},
		'type' => '->',
		'args' => [
			(int) 0 => object(Cake\Http\ServerRequest) {},
			(int) 1 => object(Cake\Http\Response) {}
		]
	],
	(int) 8 => [
		'file' => '/home/brlfuser/public_html/vendor/cakephp/cakephp/src/Http/Runner.php',
		'line' => (int) 65,
		'function' => '__invoke',
		'class' => 'Cake\Routing\Middleware\RoutingMiddleware',
		'object' => object(Cake\Routing\Middleware\RoutingMiddleware) {},
		'type' => '->',
		'args' => [
			(int) 0 => object(Cake\Http\ServerRequest) {},
			(int) 1 => object(Cake\Http\Response) {},
			(int) 2 => object(Cake\Http\Runner) {}
		]
	],
	(int) 9 => [
		'file' => '/home/brlfuser/public_html/vendor/cakephp/cakephp/src/Routing/Middleware/AssetMiddleware.php',
		'line' => (int) 88,
		'function' => '__invoke',
		'class' => 'Cake\Http\Runner',
		'object' => object(Cake\Http\Runner) {},
		'type' => '->',
		'args' => [
			(int) 0 => object(Cake\Http\ServerRequest) {},
			(int) 1 => object(Cake\Http\Response) {}
		]
	],
	(int) 10 => [
		'file' => '/home/brlfuser/public_html/vendor/cakephp/cakephp/src/Http/Runner.php',
		'line' => (int) 65,
		'function' => '__invoke',
		'class' => 'Cake\Routing\Middleware\AssetMiddleware',
		'object' => object(Cake\Routing\Middleware\AssetMiddleware) {},
		'type' => '->',
		'args' => [
			(int) 0 => object(Cake\Http\ServerRequest) {},
			(int) 1 => object(Cake\Http\Response) {},
			(int) 2 => object(Cake\Http\Runner) {}
		]
	],
	(int) 11 => [
		'file' => '/home/brlfuser/public_html/vendor/cakephp/cakephp/src/Error/Middleware/ErrorHandlerMiddleware.php',
		'line' => (int) 96,
		'function' => '__invoke',
		'class' => 'Cake\Http\Runner',
		'object' => object(Cake\Http\Runner) {},
		'type' => '->',
		'args' => [
			(int) 0 => object(Cake\Http\ServerRequest) {},
			(int) 1 => object(Cake\Http\Response) {}
		]
	],
	(int) 12 => [
		'file' => '/home/brlfuser/public_html/vendor/cakephp/cakephp/src/Http/Runner.php',
		'line' => (int) 65,
		'function' => '__invoke',
		'class' => 'Cake\Error\Middleware\ErrorHandlerMiddleware',
		'object' => object(Cake\Error\Middleware\ErrorHandlerMiddleware) {},
		'type' => '->',
		'args' => [
			(int) 0 => object(Cake\Http\ServerRequest) {},
			(int) 1 => object(Cake\Http\Response) {},
			(int) 2 => object(Cake\Http\Runner) {}
		]
	],
	(int) 13 => [
		'file' => '/home/brlfuser/public_html/vendor/cakephp/cakephp/src/Http/Runner.php',
		'line' => (int) 51,
		'function' => '__invoke',
		'class' => 'Cake\Http\Runner',
		'object' => object(Cake\Http\Runner) {},
		'type' => '->',
		'args' => [
			(int) 0 => object(Cake\Http\ServerRequest) {},
			(int) 1 => object(Cake\Http\Response) {}
		]
	],
	(int) 14 => [
		'file' => '/home/brlfuser/public_html/vendor/cakephp/cakephp/src/Http/Server.php',
		'line' => (int) 98,
		'function' => 'run',
		'class' => 'Cake\Http\Runner',
		'object' => object(Cake\Http\Runner) {},
		'type' => '->',
		'args' => [
			(int) 0 => object(Cake\Http\MiddlewareQueue) {},
			(int) 1 => object(Cake\Http\ServerRequest) {},
			(int) 2 => object(Cake\Http\Response) {}
		]
	],
	(int) 15 => [
		'file' => '/home/brlfuser/public_html/webroot/index.php',
		'line' => (int) 39,
		'function' => 'run',
		'class' => 'Cake\Http\Server',
		'object' => object(Cake\Http\Server) {},
		'type' => '->',
		'args' => []
	]
]
$frame = [
	'file' => '/home/brlfuser/public_html/src/Controller/ArtileDetailController.php',
	'line' => (int) 74,
	'function' => 'offsetGet',
	'class' => 'Cake\Http\ServerRequest',
	'object' => object(Cake\Http\ServerRequest) {
		trustProxy => false
		[protected] params => [
			[maximum depth reached]
		]
		[protected] data => [[maximum depth reached]]
		[protected] query => [[maximum depth reached]]
		[protected] cookies => [
			[maximum depth reached]
		]
		[protected] _environment => [
			[maximum depth reached]
		]
		[protected] url => 'latest-news-updates/novartis-patent-ruling-a-victory-in-battle-for-affordable-medicines-sarah-boseley-20308/print'
		[protected] base => ''
		[protected] webroot => '/'
		[protected] here => '/latest-news-updates/novartis-patent-ruling-a-victory-in-battle-for-affordable-medicines-sarah-boseley-20308/print'
		[protected] trustedProxies => [[maximum depth reached]]
		[protected] _input => null
		[protected] _detectors => [
			[maximum depth reached]
		]
		[protected] _detectorCache => [
			[maximum depth reached]
		]
		[protected] stream => object(Zend\Diactoros\PhpInputStream) {}
		[protected] uri => object(Zend\Diactoros\Uri) {}
		[protected] session => object(Cake\Http\Session) {}
		[protected] attributes => [[maximum depth reached]]
		[protected] emulatedAttributes => [
			[maximum depth reached]
		]
		[protected] uploadedFiles => [[maximum depth reached]]
		[protected] protocol => null
		[protected] requestTarget => null
		[private] deprecatedProperties => [
			[maximum depth reached]
		]
	},
	'type' => '->',
	'args' => [
		(int) 0 => 'artileslug'
	]
]
deprecationWarning - CORE/src/Core/functions.php, line 311
Cake\Http\ServerRequest::offsetGet() - CORE/src/Http/ServerRequest.php, line 2421
App\Controller\ArtileDetailController::printArticle() - APP/Controller/ArtileDetailController.php, line 74
Cake\Controller\Controller::invokeAction() - CORE/src/Controller/Controller.php, line 610
Cake\Http\ActionDispatcher::_invoke() - CORE/src/Http/ActionDispatcher.php, line 120
Cake\Http\ActionDispatcher::dispatch() - CORE/src/Http/ActionDispatcher.php, line 94
Cake\Http\BaseApplication::__invoke() - CORE/src/Http/BaseApplication.php, line 235
Cake\Http\Runner::__invoke() - CORE/src/Http/Runner.php, line 65
Cake\Routing\Middleware\RoutingMiddleware::__invoke() - CORE/src/Routing/Middleware/RoutingMiddleware.php, line 162
Cake\Http\Runner::__invoke() - CORE/src/Http/Runner.php, line 65
Cake\Routing\Middleware\AssetMiddleware::__invoke() - CORE/src/Routing/Middleware/AssetMiddleware.php, line 88
Cake\Http\Runner::__invoke() - CORE/src/Http/Runner.php, line 65
Cake\Error\Middleware\ErrorHandlerMiddleware::__invoke() - CORE/src/Error/Middleware/ErrorHandlerMiddleware.php, line 96
Cake\Http\Runner::__invoke() - CORE/src/Http/Runner.php, line 65
Cake\Http\Runner::run() - CORE/src/Http/Runner.php, line 51
Cake\Http\Server::run() - CORE/src/Http/Server.php, line 98

Warning (512): Unable to emit headers. Headers sent in file=/home/brlfuser/public_html/vendor/cakephp/cakephp/src/Error/Debugger.php line=853 [CORE/src/Http/ResponseEmitter.php, line 48]
Code Context
            if (Configure::read('debug')) {

                trigger_error($message, E_USER_WARNING);

            } else {
$response = object(Cake\Http\Response) {

	'status' => (int) 200,
	'contentType' => 'text/html',
	'headers' => [
		'Content-Type' => [
			[maximum depth reached]
		]
	],
	'file' => null,
	'fileRange' => [],
	'cookies' => object(Cake\Http\Cookie\CookieCollection) {},
	'cacheDirectives' => [],
	'body' => '<!DOCTYPE html PUBLIC "-//W3C//DTD XHTML 1.0 Transitional//EN"
        "http://www.w3.org/TR/xhtml1/DTD/xhtml1-transitional.dtd">
<html xmlns="http://www.w3.org/1999/xhtml">
<head>
    <link rel="canonical" href="https://im4change.in/<pre class="cake-error"><a href="javascript:void(0);" onclick="document.getElementById('cakeErr67f07d8435f7e-trace').style.display = (document.getElementById('cakeErr67f07d8435f7e-trace').style.display == 'none' ? '' : 'none');"><b>Notice</b> (8)</a>: Undefined variable: urlPrefix [<b>APP/Template/Layout/printlayout.ctp</b>, line <b>8</b>]<div id="cakeErr67f07d8435f7e-trace" class="cake-stack-trace" style="display: none;"><a href="javascript:void(0);" onclick="document.getElementById('cakeErr67f07d8435f7e-code').style.display = (document.getElementById('cakeErr67f07d8435f7e-code').style.display == 'none' ? '' : 'none')">Code</a> <a href="javascript:void(0);" onclick="document.getElementById('cakeErr67f07d8435f7e-context').style.display = (document.getElementById('cakeErr67f07d8435f7e-context').style.display == 'none' ? '' : 'none')">Context</a><pre id="cakeErr67f07d8435f7e-code" class="cake-code-dump" style="display: none;"><code><span style="color: #000000"><span style="color: #0000BB"></span><span style="color: #007700">&lt;</span><span style="color: #0000BB">head</span><span style="color: #007700">&gt;
</span></span></code>
<span class="code-highlight"><code><span style="color: #000000">&nbsp;&nbsp;&nbsp;&nbsp;&lt;link&nbsp;rel="canonical"&nbsp;href="<span style="color: #0000BB">&lt;?php&nbsp;</span><span style="color: #007700">echo&nbsp;</span><span style="color: #0000BB">Configure</span><span style="color: #007700">::</span><span style="color: #0000BB">read</span><span style="color: #007700">(</span><span style="color: #DD0000">'SITE_URL'</span><span style="color: #007700">);&nbsp;</span><span style="color: #0000BB">?&gt;&lt;?php&nbsp;</span><span style="color: #007700">echo&nbsp;</span><span style="color: #0000BB">$urlPrefix</span><span style="color: #007700">;</span><span style="color: #0000BB">?&gt;&lt;?php&nbsp;</span><span style="color: #007700">echo&nbsp;</span><span style="color: #0000BB">$article_current</span><span style="color: #007700">-&gt;</span><span style="color: #0000BB">category</span><span style="color: #007700">-&gt;</span><span style="color: #0000BB">slug</span><span style="color: #007700">;&nbsp;</span><span style="color: #0000BB">?&gt;</span>/<span style="color: #0000BB">&lt;?php&nbsp;</span><span style="color: #007700">echo&nbsp;</span><span style="color: #0000BB">$article_current</span><span style="color: #007700">-&gt;</span><span style="color: #0000BB">seo_url</span><span style="color: #007700">;&nbsp;</span><span style="color: #0000BB">?&gt;</span>.html"/&gt;
</span></code></span>
<code><span style="color: #000000"><span style="color: #0000BB">&nbsp;&nbsp;&nbsp;&nbsp;</span><span style="color: #007700">&lt;</span><span style="color: #0000BB">meta&nbsp;http</span><span style="color: #007700">-</span><span style="color: #0000BB">equiv</span><span style="color: #007700">=</span><span style="color: #DD0000">"Content-Type"&nbsp;</span><span style="color: #0000BB">content</span><span style="color: #007700">=</span><span style="color: #DD0000">"text/html;&nbsp;charset=utf-8"</span><span style="color: #007700">/&gt;
</span></span></code></pre><pre id="cakeErr67f07d8435f7e-context" class="cake-context" style="display: none;">$viewFile = &#039;/home/brlfuser/public_html/src/Template/Layout/printlayout.ctp&#039;
$dataForView = [
	&#039;article_current&#039; =&gt; object(App\Model\Entity\Article) {

		&#039;id&#039; =&gt; (int) 20167,
		&#039;title&#039; =&gt; &#039;Novartis patent ruling a victory in battle for affordable medicines-Sarah Boseley&#039;,
		&#039;subheading&#039; =&gt; &#039;&#039;,
		&#039;description&#039; =&gt; &#039;&lt;div align=&quot;justify&quot;&gt;
-The Guardian
&lt;/div&gt;
&lt;p align=&quot;justify&quot;&gt;
&lt;br /&gt;
&lt;em&gt;Had Novartis won, it would have set a precedent for patenting of other medicines in India, delaying their reaching the poor&lt;/em&gt;
&lt;/p&gt;
&lt;p align=&quot;justify&quot;&gt;
&amp;nbsp;
&lt;/p&gt;
&lt;p align=&quot;justify&quot;&gt;
The battle for affordable, life-saving medicines for poor countries was once waged on first-world city streets with banners and placards. But for some years now it has been a long-hard legal slog in offices and courtrooms.
&lt;/p&gt;
&lt;p align=&quot;justify&quot;&gt;
A decade or so ago, it was mostly about access to Aids drugs. Firms that made the drugs at prices too high for all but citizens of the rich world were shamed and left on the back foot by campaigners in the US and Europe.
&lt;/p&gt;
&lt;p align=&quot;justify&quot;&gt;
The activists won some famous victories, breaking the patent stranglehold of the big firms and enabling the sale of cheap generic copies. Millions of people with HIV are alive and leading normal lives in poor countries as a result.
&lt;/p&gt;
&lt;p align=&quot;justify&quot;&gt;
The multinational drug companies, however, have been working hard to prevent further erosion of their profits by generic, copycat manufacturers whom they once openly called pirates.
&lt;/p&gt;
&lt;p align=&quot;justify&quot;&gt;
The companies, with support from the US and European governments which want a profitable drug industry, they have worked to tighten patent protection for new drugs through national laws and trade agreements. India has been the main focus in its historical role as the pharmacy of the developing world.
&lt;/p&gt;
&lt;p align=&quot;justify&quot;&gt;
Under the World Trade Organisation&#039;s trade-related intellectual property rights (Trips) rules, India agreed to bring in patents for drugs in 2005. Drugs without patent protection before that date can still be copied and sold cheaply to developing countries by generics companies.
&lt;/p&gt;
&lt;p align=&quot;justify&quot;&gt;
Novartis began seeking patent protection for its cancer drug Glivec as soon as the law came into force, but as the drug was already on the market the Swiss firm could not make a standard application. Instead, it sought a patent for a slightly altered version that it said was easier for patients to absorb. Novartis argued that this was innovation under Indian law and deserving of a patent.
&lt;/p&gt;
&lt;p align=&quot;justify&quot;&gt;
The stakes were high. Glivec costs around &amp;pound;1,700 a month. Indian generic copies cost around &amp;pound;115.
&lt;/p&gt;
&lt;p align=&quot;justify&quot;&gt;
Campaigners, already concerned that the Indian patent law would delay important new medicines reaching the poor, could see that if Novartis won its legal case, the &amp;quot;evergreening&amp;quot; of drugs by other companies would become routine. Patents usually expire after 20 years, meaning it could be decades more before prices would drop.
&lt;/p&gt;
&lt;p align=&quot;justify&quot;&gt;
&amp;quot;Had the Novartis case been successful, it definitely would have extended massively the ability to patent other medicines within India,&amp;quot; said Jennifer Cohn, the medical director for M&amp;eacute;decins Sans Fronti&amp;egrave;res&#039; access campaign.
&lt;/p&gt;
&lt;p align=&quot;justify&quot;&gt;
It is an important victory, say the campaigners, but they still feel embattled. New classes of HIV drugs are being patented now in India and will not reach Africa for many years as a result, Cohn said. The same is true of new tuberculosis and hepatitis C drugs.
&lt;/p&gt;
&lt;p align=&quot;justify&quot;&gt;
Campaigners also worry about trade agreements such as the Trans-Pacific Partnership, which is being negotiated between Australia, Canada, the US, Malaysia, Chile, Mexico, Peru, Vietnam and others, and require stringent patent protection.
&lt;/p&gt;
&lt;p align=&quot;justify&quot;&gt;
The companies and their supporters, however, argue strongly that without the financial reward that long-lasting patents offer, they will not have incentives to develop new medicines. They also threaten to boycott countries that will not allow them a monopoly on their own drugs.
&lt;/p&gt;
&lt;p align=&quot;justify&quot;&gt;
No one thinks there are any simple solutions.
&lt;/p&gt;&#039;,
		&#039;credit_writer&#039; =&gt; &#039;The Guardian, 1 April, 2013, http://www.guardian.co.uk/world/2013/apr/01/novartis-patent-ruling-affordable-medicines&#039;,
		&#039;article_img&#039; =&gt; &#039;&#039;,
		&#039;article_img_thumb&#039; =&gt; &#039;&#039;,
		&#039;status&#039; =&gt; (int) 1,
		&#039;show_on_home&#039; =&gt; (int) 1,
		&#039;lang&#039; =&gt; &#039;EN&#039;,
		&#039;category_id&#039; =&gt; (int) 16,
		&#039;tag_keyword&#039; =&gt; &#039;&#039;,
		&#039;seo_url&#039; =&gt; &#039;novartis-patent-ruling-a-victory-in-battle-for-affordable-medicines-sarah-boseley-20308&#039;,
		&#039;meta_title&#039; =&gt; null,
		&#039;meta_keywords&#039; =&gt; null,
		&#039;meta_description&#039; =&gt; null,
		&#039;noindex&#039; =&gt; (int) 0,
		&#039;publish_date&#039; =&gt; object(Cake\I18n\FrozenDate) {},
		&#039;most_visit_section_id&#039; =&gt; null,
		&#039;article_big_img&#039; =&gt; null,
		&#039;liveid&#039; =&gt; (int) 20308,
		&#039;created&#039; =&gt; object(Cake\I18n\FrozenTime) {},
		&#039;modified&#039; =&gt; object(Cake\I18n\FrozenTime) {},
		&#039;edate&#039; =&gt; &#039;&#039;,
		&#039;tags&#039; =&gt; [
			[maximum depth reached]
		],
		&#039;category&#039; =&gt; object(App\Model\Entity\Category) {},
		&#039;[new]&#039; =&gt; false,
		&#039;[accessible]&#039; =&gt; [
			[maximum depth reached]
		],
		&#039;[dirty]&#039; =&gt; [[maximum depth reached]],
		&#039;[original]&#039; =&gt; [[maximum depth reached]],
		&#039;[virtual]&#039; =&gt; [[maximum depth reached]],
		&#039;[hasErrors]&#039; =&gt; false,
		&#039;[errors]&#039; =&gt; [[maximum depth reached]],
		&#039;[invalid]&#039; =&gt; [[maximum depth reached]],
		&#039;[repository]&#039; =&gt; &#039;Articles&#039;
	
	},
	&#039;articleid&#039; =&gt; (int) 20167,
	&#039;metaTitle&#039; =&gt; &#039;LATEST NEWS UPDATES | Novartis patent ruling a victory in battle for affordable medicines-Sarah Boseley&#039;,
	&#039;metaKeywords&#039; =&gt; &#039;novartis,generic drugs,patents,medicines&#039;,
	&#039;metaDesc&#039; =&gt; &#039;
-The Guardian



Had Novartis won, it would have set a precedent for patenting of other medicines in India, delaying their reaching the poor


&amp;nbsp;


The battle for affordable, life-saving medicines for poor countries was once waged on first-world city streets with banners and...&#039;,
	&#039;disp&#039; =&gt; &#039;&lt;div align=&quot;justify&quot;&gt;-The Guardian&lt;/div&gt;&lt;p align=&quot;justify&quot;&gt;&lt;br /&gt;&lt;em&gt;Had Novartis won, it would have set a precedent for patenting of other medicines in India, delaying their reaching the poor&lt;/em&gt;&lt;/p&gt;&lt;p align=&quot;justify&quot;&gt;&amp;nbsp;&lt;/p&gt;&lt;p align=&quot;justify&quot;&gt;The battle for affordable, life-saving medicines for poor countries was once waged on first-world city streets with banners and placards. But for some years now it has been a long-hard legal slog in offices and courtrooms.&lt;/p&gt;&lt;p align=&quot;justify&quot;&gt;A decade or so ago, it was mostly about access to Aids drugs. Firms that made the drugs at prices too high for all but citizens of the rich world were shamed and left on the back foot by campaigners in the US and Europe.&lt;/p&gt;&lt;p align=&quot;justify&quot;&gt;The activists won some famous victories, breaking the patent stranglehold of the big firms and enabling the sale of cheap generic copies. Millions of people with HIV are alive and leading normal lives in poor countries as a result.&lt;/p&gt;&lt;p align=&quot;justify&quot;&gt;The multinational drug companies, however, have been working hard to prevent further erosion of their profits by generic, copycat manufacturers whom they once openly called pirates.&lt;/p&gt;&lt;p align=&quot;justify&quot;&gt;The companies, with support from the US and European governments which want a profitable drug industry, they have worked to tighten patent protection for new drugs through national laws and trade agreements. India has been the main focus in its historical role as the pharmacy of the developing world.&lt;/p&gt;&lt;p align=&quot;justify&quot;&gt;Under the World Trade Organisation&#039;s trade-related intellectual property rights (Trips) rules, India agreed to bring in patents for drugs in 2005. Drugs without patent protection before that date can still be copied and sold cheaply to developing countries by generics companies.&lt;/p&gt;&lt;p align=&quot;justify&quot;&gt;Novartis began seeking patent protection for its cancer drug Glivec as soon as the law came into force, but as the drug was already on the market the Swiss firm could not make a standard application. Instead, it sought a patent for a slightly altered version that it said was easier for patients to absorb. Novartis argued that this was innovation under Indian law and deserving of a patent.&lt;/p&gt;&lt;p align=&quot;justify&quot;&gt;The stakes were high. Glivec costs around &amp;pound;1,700 a month. Indian generic copies cost around &amp;pound;115.&lt;/p&gt;&lt;p align=&quot;justify&quot;&gt;Campaigners, already concerned that the Indian patent law would delay important new medicines reaching the poor, could see that if Novartis won its legal case, the &amp;quot;evergreening&amp;quot; of drugs by other companies would become routine. Patents usually expire after 20 years, meaning it could be decades more before prices would drop.&lt;/p&gt;&lt;p align=&quot;justify&quot;&gt;&amp;quot;Had the Novartis case been successful, it definitely would have extended massively the ability to patent other medicines within India,&amp;quot; said Jennifer Cohn, the medical director for M&amp;eacute;decins Sans Fronti&amp;egrave;res&#039; access campaign.&lt;/p&gt;&lt;p align=&quot;justify&quot;&gt;It is an important victory, say the campaigners, but they still feel embattled. New classes of HIV drugs are being patented now in India and will not reach Africa for many years as a result, Cohn said. The same is true of new tuberculosis and hepatitis C drugs.&lt;/p&gt;&lt;p align=&quot;justify&quot;&gt;Campaigners also worry about trade agreements such as the Trans-Pacific Partnership, which is being negotiated between Australia, Canada, the US, Malaysia, Chile, Mexico, Peru, Vietnam and others, and require stringent patent protection.&lt;/p&gt;&lt;p align=&quot;justify&quot;&gt;The companies and their supporters, however, argue strongly that without the financial reward that long-lasting patents offer, they will not have incentives to develop new medicines. They also threaten to boycott countries that will not allow them a monopoly on their own drugs.&lt;/p&gt;&lt;p align=&quot;justify&quot;&gt;No one thinks there are any simple solutions.&lt;/p&gt;&#039;,
	&#039;lang&#039; =&gt; &#039;English&#039;,
	&#039;SITE_URL&#039; =&gt; &#039;https://im4change.in/&#039;,
	&#039;site_title&#039; =&gt; &#039;im4change&#039;,
	&#039;adminprix&#039; =&gt; &#039;admin&#039;
]
$article_current = object(App\Model\Entity\Article) {

	&#039;id&#039; =&gt; (int) 20167,
	&#039;title&#039; =&gt; &#039;Novartis patent ruling a victory in battle for affordable medicines-Sarah Boseley&#039;,
	&#039;subheading&#039; =&gt; &#039;&#039;,
	&#039;description&#039; =&gt; &#039;&lt;div align=&quot;justify&quot;&gt;
-The Guardian
&lt;/div&gt;
&lt;p align=&quot;justify&quot;&gt;
&lt;br /&gt;
&lt;em&gt;Had Novartis won, it would have set a precedent for patenting of other medicines in India, delaying their reaching the poor&lt;/em&gt;
&lt;/p&gt;
&lt;p align=&quot;justify&quot;&gt;
&amp;nbsp;
&lt;/p&gt;
&lt;p align=&quot;justify&quot;&gt;
The battle for affordable, life-saving medicines for poor countries was once waged on first-world city streets with banners and placards. But for some years now it has been a long-hard legal slog in offices and courtrooms.
&lt;/p&gt;
&lt;p align=&quot;justify&quot;&gt;
A decade or so ago, it was mostly about access to Aids drugs. Firms that made the drugs at prices too high for all but citizens of the rich world were shamed and left on the back foot by campaigners in the US and Europe.
&lt;/p&gt;
&lt;p align=&quot;justify&quot;&gt;
The activists won some famous victories, breaking the patent stranglehold of the big firms and enabling the sale of cheap generic copies. Millions of people with HIV are alive and leading normal lives in poor countries as a result.
&lt;/p&gt;
&lt;p align=&quot;justify&quot;&gt;
The multinational drug companies, however, have been working hard to prevent further erosion of their profits by generic, copycat manufacturers whom they once openly called pirates.
&lt;/p&gt;
&lt;p align=&quot;justify&quot;&gt;
The companies, with support from the US and European governments which want a profitable drug industry, they have worked to tighten patent protection for new drugs through national laws and trade agreements. India has been the main focus in its historical role as the pharmacy of the developing world.
&lt;/p&gt;
&lt;p align=&quot;justify&quot;&gt;
Under the World Trade Organisation&#039;s trade-related intellectual property rights (Trips) rules, India agreed to bring in patents for drugs in 2005. Drugs without patent protection before that date can still be copied and sold cheaply to developing countries by generics companies.
&lt;/p&gt;
&lt;p align=&quot;justify&quot;&gt;
Novartis began seeking patent protection for its cancer drug Glivec as soon as the law came into force, but as the drug was already on the market the Swiss firm could not make a standard application. Instead, it sought a patent for a slightly altered version that it said was easier for patients to absorb. Novartis argued that this was innovation under Indian law and deserving of a patent.
&lt;/p&gt;
&lt;p align=&quot;justify&quot;&gt;
The stakes were high. Glivec costs around &amp;pound;1,700 a month. Indian generic copies cost around &amp;pound;115.
&lt;/p&gt;
&lt;p align=&quot;justify&quot;&gt;
Campaigners, already concerned that the Indian patent law would delay important new medicines reaching the poor, could see that if Novartis won its legal case, the &amp;quot;evergreening&amp;quot; of drugs by other companies would become routine. Patents usually expire after 20 years, meaning it could be decades more before prices would drop.
&lt;/p&gt;
&lt;p align=&quot;justify&quot;&gt;
&amp;quot;Had the Novartis case been successful, it definitely would have extended massively the ability to patent other medicines within India,&amp;quot; said Jennifer Cohn, the medical director for M&amp;eacute;decins Sans Fronti&amp;egrave;res&#039; access campaign.
&lt;/p&gt;
&lt;p align=&quot;justify&quot;&gt;
It is an important victory, say the campaigners, but they still feel embattled. New classes of HIV drugs are being patented now in India and will not reach Africa for many years as a result, Cohn said. The same is true of new tuberculosis and hepatitis C drugs.
&lt;/p&gt;
&lt;p align=&quot;justify&quot;&gt;
Campaigners also worry about trade agreements such as the Trans-Pacific Partnership, which is being negotiated between Australia, Canada, the US, Malaysia, Chile, Mexico, Peru, Vietnam and others, and require stringent patent protection.
&lt;/p&gt;
&lt;p align=&quot;justify&quot;&gt;
The companies and their supporters, however, argue strongly that without the financial reward that long-lasting patents offer, they will not have incentives to develop new medicines. They also threaten to boycott countries that will not allow them a monopoly on their own drugs.
&lt;/p&gt;
&lt;p align=&quot;justify&quot;&gt;
No one thinks there are any simple solutions.
&lt;/p&gt;&#039;,
	&#039;credit_writer&#039; =&gt; &#039;The Guardian, 1 April, 2013, http://www.guardian.co.uk/world/2013/apr/01/novartis-patent-ruling-affordable-medicines&#039;,
	&#039;article_img&#039; =&gt; &#039;&#039;,
	&#039;article_img_thumb&#039; =&gt; &#039;&#039;,
	&#039;status&#039; =&gt; (int) 1,
	&#039;show_on_home&#039; =&gt; (int) 1,
	&#039;lang&#039; =&gt; &#039;EN&#039;,
	&#039;category_id&#039; =&gt; (int) 16,
	&#039;tag_keyword&#039; =&gt; &#039;&#039;,
	&#039;seo_url&#039; =&gt; &#039;novartis-patent-ruling-a-victory-in-battle-for-affordable-medicines-sarah-boseley-20308&#039;,
	&#039;meta_title&#039; =&gt; null,
	&#039;meta_keywords&#039; =&gt; null,
	&#039;meta_description&#039; =&gt; null,
	&#039;noindex&#039; =&gt; (int) 0,
	&#039;publish_date&#039; =&gt; object(Cake\I18n\FrozenDate) {},
	&#039;most_visit_section_id&#039; =&gt; null,
	&#039;article_big_img&#039; =&gt; null,
	&#039;liveid&#039; =&gt; (int) 20308,
	&#039;created&#039; =&gt; object(Cake\I18n\FrozenTime) {},
	&#039;modified&#039; =&gt; object(Cake\I18n\FrozenTime) {},
	&#039;edate&#039; =&gt; &#039;&#039;,
	&#039;tags&#039; =&gt; [
		(int) 0 =&gt; object(Cake\ORM\Entity) {},
		(int) 1 =&gt; object(Cake\ORM\Entity) {},
		(int) 2 =&gt; object(Cake\ORM\Entity) {},
		(int) 3 =&gt; object(Cake\ORM\Entity) {}
	],
	&#039;category&#039; =&gt; object(App\Model\Entity\Category) {},
	&#039;[new]&#039; =&gt; false,
	&#039;[accessible]&#039; =&gt; [
		&#039;*&#039; =&gt; true,
		&#039;id&#039; =&gt; false
	],
	&#039;[dirty]&#039; =&gt; [],
	&#039;[original]&#039; =&gt; [],
	&#039;[virtual]&#039; =&gt; [],
	&#039;[hasErrors]&#039; =&gt; false,
	&#039;[errors]&#039; =&gt; [],
	&#039;[invalid]&#039; =&gt; [],
	&#039;[repository]&#039; =&gt; &#039;Articles&#039;

}
$articleid = (int) 20167
$metaTitle = &#039;LATEST NEWS UPDATES | Novartis patent ruling a victory in battle for affordable medicines-Sarah Boseley&#039;
$metaKeywords = &#039;novartis,generic drugs,patents,medicines&#039;
$metaDesc = &#039;
-The Guardian



Had Novartis won, it would have set a precedent for patenting of other medicines in India, delaying their reaching the poor


&amp;nbsp;


The battle for affordable, life-saving medicines for poor countries was once waged on first-world city streets with banners and...&#039;
$disp = &#039;&lt;div align=&quot;justify&quot;&gt;-The Guardian&lt;/div&gt;&lt;p align=&quot;justify&quot;&gt;&lt;br /&gt;&lt;em&gt;Had Novartis won, it would have set a precedent for patenting of other medicines in India, delaying their reaching the poor&lt;/em&gt;&lt;/p&gt;&lt;p align=&quot;justify&quot;&gt;&amp;nbsp;&lt;/p&gt;&lt;p align=&quot;justify&quot;&gt;The battle for affordable, life-saving medicines for poor countries was once waged on first-world city streets with banners and placards. But for some years now it has been a long-hard legal slog in offices and courtrooms.&lt;/p&gt;&lt;p align=&quot;justify&quot;&gt;A decade or so ago, it was mostly about access to Aids drugs. Firms that made the drugs at prices too high for all but citizens of the rich world were shamed and left on the back foot by campaigners in the US and Europe.&lt;/p&gt;&lt;p align=&quot;justify&quot;&gt;The activists won some famous victories, breaking the patent stranglehold of the big firms and enabling the sale of cheap generic copies. Millions of people with HIV are alive and leading normal lives in poor countries as a result.&lt;/p&gt;&lt;p align=&quot;justify&quot;&gt;The multinational drug companies, however, have been working hard to prevent further erosion of their profits by generic, copycat manufacturers whom they once openly called pirates.&lt;/p&gt;&lt;p align=&quot;justify&quot;&gt;The companies, with support from the US and European governments which want a profitable drug industry, they have worked to tighten patent protection for new drugs through national laws and trade agreements. India has been the main focus in its historical role as the pharmacy of the developing world.&lt;/p&gt;&lt;p align=&quot;justify&quot;&gt;Under the World Trade Organisation&#039;s trade-related intellectual property rights (Trips) rules, India agreed to bring in patents for drugs in 2005. Drugs without patent protection before that date can still be copied and sold cheaply to developing countries by generics companies.&lt;/p&gt;&lt;p align=&quot;justify&quot;&gt;Novartis began seeking patent protection for its cancer drug Glivec as soon as the law came into force, but as the drug was already on the market the Swiss firm could not make a standard application. Instead, it sought a patent for a slightly altered version that it said was easier for patients to absorb. Novartis argued that this was innovation under Indian law and deserving of a patent.&lt;/p&gt;&lt;p align=&quot;justify&quot;&gt;The stakes were high. Glivec costs around &amp;pound;1,700 a month. Indian generic copies cost around &amp;pound;115.&lt;/p&gt;&lt;p align=&quot;justify&quot;&gt;Campaigners, already concerned that the Indian patent law would delay important new medicines reaching the poor, could see that if Novartis won its legal case, the &amp;quot;evergreening&amp;quot; of drugs by other companies would become routine. Patents usually expire after 20 years, meaning it could be decades more before prices would drop.&lt;/p&gt;&lt;p align=&quot;justify&quot;&gt;&amp;quot;Had the Novartis case been successful, it definitely would have extended massively the ability to patent other medicines within India,&amp;quot; said Jennifer Cohn, the medical director for M&amp;eacute;decins Sans Fronti&amp;egrave;res&#039; access campaign.&lt;/p&gt;&lt;p align=&quot;justify&quot;&gt;It is an important victory, say the campaigners, but they still feel embattled. New classes of HIV drugs are being patented now in India and will not reach Africa for many years as a result, Cohn said. The same is true of new tuberculosis and hepatitis C drugs.&lt;/p&gt;&lt;p align=&quot;justify&quot;&gt;Campaigners also worry about trade agreements such as the Trans-Pacific Partnership, which is being negotiated between Australia, Canada, the US, Malaysia, Chile, Mexico, Peru, Vietnam and others, and require stringent patent protection.&lt;/p&gt;&lt;p align=&quot;justify&quot;&gt;The companies and their supporters, however, argue strongly that without the financial reward that long-lasting patents offer, they will not have incentives to develop new medicines. They also threaten to boycott countries that will not allow them a monopoly on their own drugs.&lt;/p&gt;&lt;p align=&quot;justify&quot;&gt;No one thinks there are any simple solutions.&lt;/p&gt;&#039;
$lang = &#039;English&#039;
$SITE_URL = &#039;https://im4change.in/&#039;
$site_title = &#039;im4change&#039;
$adminprix = &#039;admin&#039;</pre><pre class="stack-trace">include - APP/Template/Layout/printlayout.ctp, line 8
Cake\View\View::_evaluate() - CORE/src/View/View.php, line 1413
Cake\View\View::_render() - CORE/src/View/View.php, line 1374
Cake\View\View::renderLayout() - CORE/src/View/View.php, line 927
Cake\View\View::render() - CORE/src/View/View.php, line 885
Cake\Controller\Controller::render() - CORE/src/Controller/Controller.php, line 791
Cake\Http\ActionDispatcher::_invoke() - CORE/src/Http/ActionDispatcher.php, line 126
Cake\Http\ActionDispatcher::dispatch() - CORE/src/Http/ActionDispatcher.php, line 94
Cake\Http\BaseApplication::__invoke() - CORE/src/Http/BaseApplication.php, line 235
Cake\Http\Runner::__invoke() - CORE/src/Http/Runner.php, line 65
Cake\Routing\Middleware\RoutingMiddleware::__invoke() - CORE/src/Routing/Middleware/RoutingMiddleware.php, line 162
Cake\Http\Runner::__invoke() - CORE/src/Http/Runner.php, line 65
Cake\Routing\Middleware\AssetMiddleware::__invoke() - CORE/src/Routing/Middleware/AssetMiddleware.php, line 88
Cake\Http\Runner::__invoke() - CORE/src/Http/Runner.php, line 65
Cake\Error\Middleware\ErrorHandlerMiddleware::__invoke() - CORE/src/Error/Middleware/ErrorHandlerMiddleware.php, line 96
Cake\Http\Runner::__invoke() - CORE/src/Http/Runner.php, line 65
Cake\Http\Runner::run() - CORE/src/Http/Runner.php, line 51</pre></div></pre>latest-news-updates/novartis-patent-ruling-a-victory-in-battle-for-affordable-medicines-sarah-boseley-20308.html"/>
    <meta http-equiv="Content-Type" content="text/html; charset=utf-8"/>
    <link href="https://im4change.in/css/control.css" rel="stylesheet" type="text/css"
          media="all"/>
    <title>LATEST NEWS UPDATES | Novartis patent ruling a victory in battle for affordable medicines-Sarah Boseley | Im4change.org</title>
    <meta name="description" content="
-The Guardian



Had Novartis won, it would have set a precedent for patenting of other medicines in India, delaying their reaching the poor


&nbsp;


The battle for affordable, life-saving medicines for poor countries was once waged on first-world city streets with banners and..."/>
    <script src="https://im4change.in/js/jquery-1.10.2.js"></script>
    <script type="text/javascript" src="https://im4change.in/js/jquery-migrate.min.js"></script>
    <script language="javascript" type="text/javascript">

        $(document).ready(function () {
            var img = $("img")[0]; // Get my img elem
            var pic_real_width, pic_real_height;
            $("<img/>") // Make in memory copy of image to avoid css issues
                .attr("src", $(img).attr("src"))
                .load(function () {
                    pic_real_width = this.width;   // Note: $(this).width() will not
                    pic_real_height = this.height; // work for in memory images.
                });
        });
    </script>
    <style type="text/css">
        @media screen {
            div.divFooter {
                display: block;
            }
        }

        @media print {
            .printbutton {
                display: none !important;
            }
        }
    </style>
</head>
<body>
<table cellpadding="0" cellspacing="0" border="0" width="98%" align="center">
    <tr>
        <td class="top_bg">
            <div class="divFooter">
                <img src="https://im4change.in/images/logo1.jpg" height="59" border="0"
                     alt="Resource centre on India's rural distress" style="padding-top:14px;"/>
            </div>

        </td>
    </tr>
    <tr>
        <td id="topspace">&nbsp;</td>
    </tr>

    <tr id="topspace">
        <td>&nbsp;</td>
    </tr>
    <tr>
        <td height="50" style="border-bottom:1px solid #000; padding-top:10px;" class="printbutton">
            <form><input type="button" value=" Print this page "
                         onclick="window.print();return false;"/></form>
        </td>
    </tr>

    <tr>
        <td width="100%">
            <h1 class="news_headlines" style="font-style:normal">
                <strong>Novartis patent ruling a victory in battle for affordable medicines-Sarah Boseley</strong></h1>
        </td>
    </tr>
    <tr>
        <td width="100%" style="font-family:Arial, 'Segoe Script', 'Segoe UI', sans-serif, serif"><font size="3">
                <div align="justify">-The Guardian</div><p align="justify"><br /><em>Had Novartis won, it would have set a precedent for patenting of other medicines in India, delaying their reaching the poor</em></p><p align="justify">&nbsp;</p><p align="justify">The battle for affordable, life-saving medicines for poor countries was once waged on first-world city streets with banners and placards. But for some years now it has been a long-hard legal slog in offices and courtrooms.</p><p align="justify">A decade or so ago, it was mostly about access to Aids drugs. Firms that made the drugs at prices too high for all but citizens of the rich world were shamed and left on the back foot by campaigners in the US and Europe.</p><p align="justify">The activists won some famous victories, breaking the patent stranglehold of the big firms and enabling the sale of cheap generic copies. Millions of people with HIV are alive and leading normal lives in poor countries as a result.</p><p align="justify">The multinational drug companies, however, have been working hard to prevent further erosion of their profits by generic, copycat manufacturers whom they once openly called pirates.</p><p align="justify">The companies, with support from the US and European governments which want a profitable drug industry, they have worked to tighten patent protection for new drugs through national laws and trade agreements. India has been the main focus in its historical role as the pharmacy of the developing world.</p><p align="justify">Under the World Trade Organisation's trade-related intellectual property rights (Trips) rules, India agreed to bring in patents for drugs in 2005. Drugs without patent protection before that date can still be copied and sold cheaply to developing countries by generics companies.</p><p align="justify">Novartis began seeking patent protection for its cancer drug Glivec as soon as the law came into force, but as the drug was already on the market the Swiss firm could not make a standard application. Instead, it sought a patent for a slightly altered version that it said was easier for patients to absorb. Novartis argued that this was innovation under Indian law and deserving of a patent.</p><p align="justify">The stakes were high. Glivec costs around &pound;1,700 a month. Indian generic copies cost around &pound;115.</p><p align="justify">Campaigners, already concerned that the Indian patent law would delay important new medicines reaching the poor, could see that if Novartis won its legal case, the &quot;evergreening&quot; of drugs by other companies would become routine. Patents usually expire after 20 years, meaning it could be decades more before prices would drop.</p><p align="justify">&quot;Had the Novartis case been successful, it definitely would have extended massively the ability to patent other medicines within India,&quot; said Jennifer Cohn, the medical director for M&eacute;decins Sans Fronti&egrave;res' access campaign.</p><p align="justify">It is an important victory, say the campaigners, but they still feel embattled. New classes of HIV drugs are being patented now in India and will not reach Africa for many years as a result, Cohn said. The same is true of new tuberculosis and hepatitis C drugs.</p><p align="justify">Campaigners also worry about trade agreements such as the Trans-Pacific Partnership, which is being negotiated between Australia, Canada, the US, Malaysia, Chile, Mexico, Peru, Vietnam and others, and require stringent patent protection.</p><p align="justify">The companies and their supporters, however, argue strongly that without the financial reward that long-lasting patents offer, they will not have incentives to develop new medicines. They also threaten to boycott countries that will not allow them a monopoly on their own drugs.</p><p align="justify">No one thinks there are any simple solutions.</p>               </font>
        </td>
    </tr>
    <tr>
        <td>&nbsp;</td>
    </tr>

    <tr>
        <td height="50" style="border-top:1px solid #000; border-bottom:1px solid #000;padding-top:10px;">
            <form><input type="button" value=" Print this page "
                         onclick="window.print();return false;"/></form>
        </td>
    </tr>
</table></body>
</html>'

}
$maxBufferLength = (int) 8192
$file = '/home/brlfuser/public_html/vendor/cakephp/cakephp/src/Error/Debugger.php'
$line = (int) 853
$message = 'Unable to emit headers. Headers sent in file=/home/brlfuser/public_html/vendor/cakephp/cakephp/src/Error/Debugger.php line=853'
Cake\Http\ResponseEmitter::emit() - CORE/src/Http/ResponseEmitter.php, line 48
Cake\Http\Server::emit() - CORE/src/Http/Server.php, line 141
[main] - ROOT/webroot/index.php, line 39

Warning (2): Cannot modify header information - headers already sent by (output started at /home/brlfuser/public_html/vendor/cakephp/cakephp/src/Error/Debugger.php:853) [CORE/src/Http/ResponseEmitter.php, line 148]
Code Context
            $response->getStatusCode(),

            ($reasonPhrase ? ' ' . $reasonPhrase : '')

        ));
$response = object(Cake\Http\Response) {

	'status' => (int) 200,
	'contentType' => 'text/html',
	'headers' => [
		'Content-Type' => [
			[maximum depth reached]
		]
	],
	'file' => null,
	'fileRange' => [],
	'cookies' => object(Cake\Http\Cookie\CookieCollection) {},
	'cacheDirectives' => [],
	'body' => '<!DOCTYPE html PUBLIC "-//W3C//DTD XHTML 1.0 Transitional//EN"
        "http://www.w3.org/TR/xhtml1/DTD/xhtml1-transitional.dtd">
<html xmlns="http://www.w3.org/1999/xhtml">
<head>
    <link rel="canonical" href="https://im4change.in/<pre class="cake-error"><a href="javascript:void(0);" onclick="document.getElementById('cakeErr67f07d8435f7e-trace').style.display = (document.getElementById('cakeErr67f07d8435f7e-trace').style.display == 'none' ? '' : 'none');"><b>Notice</b> (8)</a>: Undefined variable: urlPrefix [<b>APP/Template/Layout/printlayout.ctp</b>, line <b>8</b>]<div id="cakeErr67f07d8435f7e-trace" class="cake-stack-trace" style="display: none;"><a href="javascript:void(0);" onclick="document.getElementById('cakeErr67f07d8435f7e-code').style.display = (document.getElementById('cakeErr67f07d8435f7e-code').style.display == 'none' ? '' : 'none')">Code</a> <a href="javascript:void(0);" onclick="document.getElementById('cakeErr67f07d8435f7e-context').style.display = (document.getElementById('cakeErr67f07d8435f7e-context').style.display == 'none' ? '' : 'none')">Context</a><pre id="cakeErr67f07d8435f7e-code" class="cake-code-dump" style="display: none;"><code><span style="color: #000000"><span style="color: #0000BB"></span><span style="color: #007700">&lt;</span><span style="color: #0000BB">head</span><span style="color: #007700">&gt;
</span></span></code>
<span class="code-highlight"><code><span style="color: #000000">&nbsp;&nbsp;&nbsp;&nbsp;&lt;link&nbsp;rel="canonical"&nbsp;href="<span style="color: #0000BB">&lt;?php&nbsp;</span><span style="color: #007700">echo&nbsp;</span><span style="color: #0000BB">Configure</span><span style="color: #007700">::</span><span style="color: #0000BB">read</span><span style="color: #007700">(</span><span style="color: #DD0000">'SITE_URL'</span><span style="color: #007700">);&nbsp;</span><span style="color: #0000BB">?&gt;&lt;?php&nbsp;</span><span style="color: #007700">echo&nbsp;</span><span style="color: #0000BB">$urlPrefix</span><span style="color: #007700">;</span><span style="color: #0000BB">?&gt;&lt;?php&nbsp;</span><span style="color: #007700">echo&nbsp;</span><span style="color: #0000BB">$article_current</span><span style="color: #007700">-&gt;</span><span style="color: #0000BB">category</span><span style="color: #007700">-&gt;</span><span style="color: #0000BB">slug</span><span style="color: #007700">;&nbsp;</span><span style="color: #0000BB">?&gt;</span>/<span style="color: #0000BB">&lt;?php&nbsp;</span><span style="color: #007700">echo&nbsp;</span><span style="color: #0000BB">$article_current</span><span style="color: #007700">-&gt;</span><span style="color: #0000BB">seo_url</span><span style="color: #007700">;&nbsp;</span><span style="color: #0000BB">?&gt;</span>.html"/&gt;
</span></code></span>
<code><span style="color: #000000"><span style="color: #0000BB">&nbsp;&nbsp;&nbsp;&nbsp;</span><span style="color: #007700">&lt;</span><span style="color: #0000BB">meta&nbsp;http</span><span style="color: #007700">-</span><span style="color: #0000BB">equiv</span><span style="color: #007700">=</span><span style="color: #DD0000">"Content-Type"&nbsp;</span><span style="color: #0000BB">content</span><span style="color: #007700">=</span><span style="color: #DD0000">"text/html;&nbsp;charset=utf-8"</span><span style="color: #007700">/&gt;
</span></span></code></pre><pre id="cakeErr67f07d8435f7e-context" class="cake-context" style="display: none;">$viewFile = &#039;/home/brlfuser/public_html/src/Template/Layout/printlayout.ctp&#039;
$dataForView = [
	&#039;article_current&#039; =&gt; object(App\Model\Entity\Article) {

		&#039;id&#039; =&gt; (int) 20167,
		&#039;title&#039; =&gt; &#039;Novartis patent ruling a victory in battle for affordable medicines-Sarah Boseley&#039;,
		&#039;subheading&#039; =&gt; &#039;&#039;,
		&#039;description&#039; =&gt; &#039;&lt;div align=&quot;justify&quot;&gt;
-The Guardian
&lt;/div&gt;
&lt;p align=&quot;justify&quot;&gt;
&lt;br /&gt;
&lt;em&gt;Had Novartis won, it would have set a precedent for patenting of other medicines in India, delaying their reaching the poor&lt;/em&gt;
&lt;/p&gt;
&lt;p align=&quot;justify&quot;&gt;
&amp;nbsp;
&lt;/p&gt;
&lt;p align=&quot;justify&quot;&gt;
The battle for affordable, life-saving medicines for poor countries was once waged on first-world city streets with banners and placards. But for some years now it has been a long-hard legal slog in offices and courtrooms.
&lt;/p&gt;
&lt;p align=&quot;justify&quot;&gt;
A decade or so ago, it was mostly about access to Aids drugs. Firms that made the drugs at prices too high for all but citizens of the rich world were shamed and left on the back foot by campaigners in the US and Europe.
&lt;/p&gt;
&lt;p align=&quot;justify&quot;&gt;
The activists won some famous victories, breaking the patent stranglehold of the big firms and enabling the sale of cheap generic copies. Millions of people with HIV are alive and leading normal lives in poor countries as a result.
&lt;/p&gt;
&lt;p align=&quot;justify&quot;&gt;
The multinational drug companies, however, have been working hard to prevent further erosion of their profits by generic, copycat manufacturers whom they once openly called pirates.
&lt;/p&gt;
&lt;p align=&quot;justify&quot;&gt;
The companies, with support from the US and European governments which want a profitable drug industry, they have worked to tighten patent protection for new drugs through national laws and trade agreements. India has been the main focus in its historical role as the pharmacy of the developing world.
&lt;/p&gt;
&lt;p align=&quot;justify&quot;&gt;
Under the World Trade Organisation&#039;s trade-related intellectual property rights (Trips) rules, India agreed to bring in patents for drugs in 2005. Drugs without patent protection before that date can still be copied and sold cheaply to developing countries by generics companies.
&lt;/p&gt;
&lt;p align=&quot;justify&quot;&gt;
Novartis began seeking patent protection for its cancer drug Glivec as soon as the law came into force, but as the drug was already on the market the Swiss firm could not make a standard application. Instead, it sought a patent for a slightly altered version that it said was easier for patients to absorb. Novartis argued that this was innovation under Indian law and deserving of a patent.
&lt;/p&gt;
&lt;p align=&quot;justify&quot;&gt;
The stakes were high. Glivec costs around &amp;pound;1,700 a month. Indian generic copies cost around &amp;pound;115.
&lt;/p&gt;
&lt;p align=&quot;justify&quot;&gt;
Campaigners, already concerned that the Indian patent law would delay important new medicines reaching the poor, could see that if Novartis won its legal case, the &amp;quot;evergreening&amp;quot; of drugs by other companies would become routine. Patents usually expire after 20 years, meaning it could be decades more before prices would drop.
&lt;/p&gt;
&lt;p align=&quot;justify&quot;&gt;
&amp;quot;Had the Novartis case been successful, it definitely would have extended massively the ability to patent other medicines within India,&amp;quot; said Jennifer Cohn, the medical director for M&amp;eacute;decins Sans Fronti&amp;egrave;res&#039; access campaign.
&lt;/p&gt;
&lt;p align=&quot;justify&quot;&gt;
It is an important victory, say the campaigners, but they still feel embattled. New classes of HIV drugs are being patented now in India and will not reach Africa for many years as a result, Cohn said. The same is true of new tuberculosis and hepatitis C drugs.
&lt;/p&gt;
&lt;p align=&quot;justify&quot;&gt;
Campaigners also worry about trade agreements such as the Trans-Pacific Partnership, which is being negotiated between Australia, Canada, the US, Malaysia, Chile, Mexico, Peru, Vietnam and others, and require stringent patent protection.
&lt;/p&gt;
&lt;p align=&quot;justify&quot;&gt;
The companies and their supporters, however, argue strongly that without the financial reward that long-lasting patents offer, they will not have incentives to develop new medicines. They also threaten to boycott countries that will not allow them a monopoly on their own drugs.
&lt;/p&gt;
&lt;p align=&quot;justify&quot;&gt;
No one thinks there are any simple solutions.
&lt;/p&gt;&#039;,
		&#039;credit_writer&#039; =&gt; &#039;The Guardian, 1 April, 2013, http://www.guardian.co.uk/world/2013/apr/01/novartis-patent-ruling-affordable-medicines&#039;,
		&#039;article_img&#039; =&gt; &#039;&#039;,
		&#039;article_img_thumb&#039; =&gt; &#039;&#039;,
		&#039;status&#039; =&gt; (int) 1,
		&#039;show_on_home&#039; =&gt; (int) 1,
		&#039;lang&#039; =&gt; &#039;EN&#039;,
		&#039;category_id&#039; =&gt; (int) 16,
		&#039;tag_keyword&#039; =&gt; &#039;&#039;,
		&#039;seo_url&#039; =&gt; &#039;novartis-patent-ruling-a-victory-in-battle-for-affordable-medicines-sarah-boseley-20308&#039;,
		&#039;meta_title&#039; =&gt; null,
		&#039;meta_keywords&#039; =&gt; null,
		&#039;meta_description&#039; =&gt; null,
		&#039;noindex&#039; =&gt; (int) 0,
		&#039;publish_date&#039; =&gt; object(Cake\I18n\FrozenDate) {},
		&#039;most_visit_section_id&#039; =&gt; null,
		&#039;article_big_img&#039; =&gt; null,
		&#039;liveid&#039; =&gt; (int) 20308,
		&#039;created&#039; =&gt; object(Cake\I18n\FrozenTime) {},
		&#039;modified&#039; =&gt; object(Cake\I18n\FrozenTime) {},
		&#039;edate&#039; =&gt; &#039;&#039;,
		&#039;tags&#039; =&gt; [
			[maximum depth reached]
		],
		&#039;category&#039; =&gt; object(App\Model\Entity\Category) {},
		&#039;[new]&#039; =&gt; false,
		&#039;[accessible]&#039; =&gt; [
			[maximum depth reached]
		],
		&#039;[dirty]&#039; =&gt; [[maximum depth reached]],
		&#039;[original]&#039; =&gt; [[maximum depth reached]],
		&#039;[virtual]&#039; =&gt; [[maximum depth reached]],
		&#039;[hasErrors]&#039; =&gt; false,
		&#039;[errors]&#039; =&gt; [[maximum depth reached]],
		&#039;[invalid]&#039; =&gt; [[maximum depth reached]],
		&#039;[repository]&#039; =&gt; &#039;Articles&#039;
	
	},
	&#039;articleid&#039; =&gt; (int) 20167,
	&#039;metaTitle&#039; =&gt; &#039;LATEST NEWS UPDATES | Novartis patent ruling a victory in battle for affordable medicines-Sarah Boseley&#039;,
	&#039;metaKeywords&#039; =&gt; &#039;novartis,generic drugs,patents,medicines&#039;,
	&#039;metaDesc&#039; =&gt; &#039;
-The Guardian



Had Novartis won, it would have set a precedent for patenting of other medicines in India, delaying their reaching the poor


&amp;nbsp;


The battle for affordable, life-saving medicines for poor countries was once waged on first-world city streets with banners and...&#039;,
	&#039;disp&#039; =&gt; &#039;&lt;div align=&quot;justify&quot;&gt;-The Guardian&lt;/div&gt;&lt;p align=&quot;justify&quot;&gt;&lt;br /&gt;&lt;em&gt;Had Novartis won, it would have set a precedent for patenting of other medicines in India, delaying their reaching the poor&lt;/em&gt;&lt;/p&gt;&lt;p align=&quot;justify&quot;&gt;&amp;nbsp;&lt;/p&gt;&lt;p align=&quot;justify&quot;&gt;The battle for affordable, life-saving medicines for poor countries was once waged on first-world city streets with banners and placards. But for some years now it has been a long-hard legal slog in offices and courtrooms.&lt;/p&gt;&lt;p align=&quot;justify&quot;&gt;A decade or so ago, it was mostly about access to Aids drugs. Firms that made the drugs at prices too high for all but citizens of the rich world were shamed and left on the back foot by campaigners in the US and Europe.&lt;/p&gt;&lt;p align=&quot;justify&quot;&gt;The activists won some famous victories, breaking the patent stranglehold of the big firms and enabling the sale of cheap generic copies. Millions of people with HIV are alive and leading normal lives in poor countries as a result.&lt;/p&gt;&lt;p align=&quot;justify&quot;&gt;The multinational drug companies, however, have been working hard to prevent further erosion of their profits by generic, copycat manufacturers whom they once openly called pirates.&lt;/p&gt;&lt;p align=&quot;justify&quot;&gt;The companies, with support from the US and European governments which want a profitable drug industry, they have worked to tighten patent protection for new drugs through national laws and trade agreements. India has been the main focus in its historical role as the pharmacy of the developing world.&lt;/p&gt;&lt;p align=&quot;justify&quot;&gt;Under the World Trade Organisation&#039;s trade-related intellectual property rights (Trips) rules, India agreed to bring in patents for drugs in 2005. Drugs without patent protection before that date can still be copied and sold cheaply to developing countries by generics companies.&lt;/p&gt;&lt;p align=&quot;justify&quot;&gt;Novartis began seeking patent protection for its cancer drug Glivec as soon as the law came into force, but as the drug was already on the market the Swiss firm could not make a standard application. Instead, it sought a patent for a slightly altered version that it said was easier for patients to absorb. Novartis argued that this was innovation under Indian law and deserving of a patent.&lt;/p&gt;&lt;p align=&quot;justify&quot;&gt;The stakes were high. Glivec costs around &amp;pound;1,700 a month. Indian generic copies cost around &amp;pound;115.&lt;/p&gt;&lt;p align=&quot;justify&quot;&gt;Campaigners, already concerned that the Indian patent law would delay important new medicines reaching the poor, could see that if Novartis won its legal case, the &amp;quot;evergreening&amp;quot; of drugs by other companies would become routine. Patents usually expire after 20 years, meaning it could be decades more before prices would drop.&lt;/p&gt;&lt;p align=&quot;justify&quot;&gt;&amp;quot;Had the Novartis case been successful, it definitely would have extended massively the ability to patent other medicines within India,&amp;quot; said Jennifer Cohn, the medical director for M&amp;eacute;decins Sans Fronti&amp;egrave;res&#039; access campaign.&lt;/p&gt;&lt;p align=&quot;justify&quot;&gt;It is an important victory, say the campaigners, but they still feel embattled. New classes of HIV drugs are being patented now in India and will not reach Africa for many years as a result, Cohn said. The same is true of new tuberculosis and hepatitis C drugs.&lt;/p&gt;&lt;p align=&quot;justify&quot;&gt;Campaigners also worry about trade agreements such as the Trans-Pacific Partnership, which is being negotiated between Australia, Canada, the US, Malaysia, Chile, Mexico, Peru, Vietnam and others, and require stringent patent protection.&lt;/p&gt;&lt;p align=&quot;justify&quot;&gt;The companies and their supporters, however, argue strongly that without the financial reward that long-lasting patents offer, they will not have incentives to develop new medicines. They also threaten to boycott countries that will not allow them a monopoly on their own drugs.&lt;/p&gt;&lt;p align=&quot;justify&quot;&gt;No one thinks there are any simple solutions.&lt;/p&gt;&#039;,
	&#039;lang&#039; =&gt; &#039;English&#039;,
	&#039;SITE_URL&#039; =&gt; &#039;https://im4change.in/&#039;,
	&#039;site_title&#039; =&gt; &#039;im4change&#039;,
	&#039;adminprix&#039; =&gt; &#039;admin&#039;
]
$article_current = object(App\Model\Entity\Article) {

	&#039;id&#039; =&gt; (int) 20167,
	&#039;title&#039; =&gt; &#039;Novartis patent ruling a victory in battle for affordable medicines-Sarah Boseley&#039;,
	&#039;subheading&#039; =&gt; &#039;&#039;,
	&#039;description&#039; =&gt; &#039;&lt;div align=&quot;justify&quot;&gt;
-The Guardian
&lt;/div&gt;
&lt;p align=&quot;justify&quot;&gt;
&lt;br /&gt;
&lt;em&gt;Had Novartis won, it would have set a precedent for patenting of other medicines in India, delaying their reaching the poor&lt;/em&gt;
&lt;/p&gt;
&lt;p align=&quot;justify&quot;&gt;
&amp;nbsp;
&lt;/p&gt;
&lt;p align=&quot;justify&quot;&gt;
The battle for affordable, life-saving medicines for poor countries was once waged on first-world city streets with banners and placards. But for some years now it has been a long-hard legal slog in offices and courtrooms.
&lt;/p&gt;
&lt;p align=&quot;justify&quot;&gt;
A decade or so ago, it was mostly about access to Aids drugs. Firms that made the drugs at prices too high for all but citizens of the rich world were shamed and left on the back foot by campaigners in the US and Europe.
&lt;/p&gt;
&lt;p align=&quot;justify&quot;&gt;
The activists won some famous victories, breaking the patent stranglehold of the big firms and enabling the sale of cheap generic copies. Millions of people with HIV are alive and leading normal lives in poor countries as a result.
&lt;/p&gt;
&lt;p align=&quot;justify&quot;&gt;
The multinational drug companies, however, have been working hard to prevent further erosion of their profits by generic, copycat manufacturers whom they once openly called pirates.
&lt;/p&gt;
&lt;p align=&quot;justify&quot;&gt;
The companies, with support from the US and European governments which want a profitable drug industry, they have worked to tighten patent protection for new drugs through national laws and trade agreements. India has been the main focus in its historical role as the pharmacy of the developing world.
&lt;/p&gt;
&lt;p align=&quot;justify&quot;&gt;
Under the World Trade Organisation&#039;s trade-related intellectual property rights (Trips) rules, India agreed to bring in patents for drugs in 2005. Drugs without patent protection before that date can still be copied and sold cheaply to developing countries by generics companies.
&lt;/p&gt;
&lt;p align=&quot;justify&quot;&gt;
Novartis began seeking patent protection for its cancer drug Glivec as soon as the law came into force, but as the drug was already on the market the Swiss firm could not make a standard application. Instead, it sought a patent for a slightly altered version that it said was easier for patients to absorb. Novartis argued that this was innovation under Indian law and deserving of a patent.
&lt;/p&gt;
&lt;p align=&quot;justify&quot;&gt;
The stakes were high. Glivec costs around &amp;pound;1,700 a month. Indian generic copies cost around &amp;pound;115.
&lt;/p&gt;
&lt;p align=&quot;justify&quot;&gt;
Campaigners, already concerned that the Indian patent law would delay important new medicines reaching the poor, could see that if Novartis won its legal case, the &amp;quot;evergreening&amp;quot; of drugs by other companies would become routine. Patents usually expire after 20 years, meaning it could be decades more before prices would drop.
&lt;/p&gt;
&lt;p align=&quot;justify&quot;&gt;
&amp;quot;Had the Novartis case been successful, it definitely would have extended massively the ability to patent other medicines within India,&amp;quot; said Jennifer Cohn, the medical director for M&amp;eacute;decins Sans Fronti&amp;egrave;res&#039; access campaign.
&lt;/p&gt;
&lt;p align=&quot;justify&quot;&gt;
It is an important victory, say the campaigners, but they still feel embattled. New classes of HIV drugs are being patented now in India and will not reach Africa for many years as a result, Cohn said. The same is true of new tuberculosis and hepatitis C drugs.
&lt;/p&gt;
&lt;p align=&quot;justify&quot;&gt;
Campaigners also worry about trade agreements such as the Trans-Pacific Partnership, which is being negotiated between Australia, Canada, the US, Malaysia, Chile, Mexico, Peru, Vietnam and others, and require stringent patent protection.
&lt;/p&gt;
&lt;p align=&quot;justify&quot;&gt;
The companies and their supporters, however, argue strongly that without the financial reward that long-lasting patents offer, they will not have incentives to develop new medicines. They also threaten to boycott countries that will not allow them a monopoly on their own drugs.
&lt;/p&gt;
&lt;p align=&quot;justify&quot;&gt;
No one thinks there are any simple solutions.
&lt;/p&gt;&#039;,
	&#039;credit_writer&#039; =&gt; &#039;The Guardian, 1 April, 2013, http://www.guardian.co.uk/world/2013/apr/01/novartis-patent-ruling-affordable-medicines&#039;,
	&#039;article_img&#039; =&gt; &#039;&#039;,
	&#039;article_img_thumb&#039; =&gt; &#039;&#039;,
	&#039;status&#039; =&gt; (int) 1,
	&#039;show_on_home&#039; =&gt; (int) 1,
	&#039;lang&#039; =&gt; &#039;EN&#039;,
	&#039;category_id&#039; =&gt; (int) 16,
	&#039;tag_keyword&#039; =&gt; &#039;&#039;,
	&#039;seo_url&#039; =&gt; &#039;novartis-patent-ruling-a-victory-in-battle-for-affordable-medicines-sarah-boseley-20308&#039;,
	&#039;meta_title&#039; =&gt; null,
	&#039;meta_keywords&#039; =&gt; null,
	&#039;meta_description&#039; =&gt; null,
	&#039;noindex&#039; =&gt; (int) 0,
	&#039;publish_date&#039; =&gt; object(Cake\I18n\FrozenDate) {},
	&#039;most_visit_section_id&#039; =&gt; null,
	&#039;article_big_img&#039; =&gt; null,
	&#039;liveid&#039; =&gt; (int) 20308,
	&#039;created&#039; =&gt; object(Cake\I18n\FrozenTime) {},
	&#039;modified&#039; =&gt; object(Cake\I18n\FrozenTime) {},
	&#039;edate&#039; =&gt; &#039;&#039;,
	&#039;tags&#039; =&gt; [
		(int) 0 =&gt; object(Cake\ORM\Entity) {},
		(int) 1 =&gt; object(Cake\ORM\Entity) {},
		(int) 2 =&gt; object(Cake\ORM\Entity) {},
		(int) 3 =&gt; object(Cake\ORM\Entity) {}
	],
	&#039;category&#039; =&gt; object(App\Model\Entity\Category) {},
	&#039;[new]&#039; =&gt; false,
	&#039;[accessible]&#039; =&gt; [
		&#039;*&#039; =&gt; true,
		&#039;id&#039; =&gt; false
	],
	&#039;[dirty]&#039; =&gt; [],
	&#039;[original]&#039; =&gt; [],
	&#039;[virtual]&#039; =&gt; [],
	&#039;[hasErrors]&#039; =&gt; false,
	&#039;[errors]&#039; =&gt; [],
	&#039;[invalid]&#039; =&gt; [],
	&#039;[repository]&#039; =&gt; &#039;Articles&#039;

}
$articleid = (int) 20167
$metaTitle = &#039;LATEST NEWS UPDATES | Novartis patent ruling a victory in battle for affordable medicines-Sarah Boseley&#039;
$metaKeywords = &#039;novartis,generic drugs,patents,medicines&#039;
$metaDesc = &#039;
-The Guardian



Had Novartis won, it would have set a precedent for patenting of other medicines in India, delaying their reaching the poor


&amp;nbsp;


The battle for affordable, life-saving medicines for poor countries was once waged on first-world city streets with banners and...&#039;
$disp = &#039;&lt;div align=&quot;justify&quot;&gt;-The Guardian&lt;/div&gt;&lt;p align=&quot;justify&quot;&gt;&lt;br /&gt;&lt;em&gt;Had Novartis won, it would have set a precedent for patenting of other medicines in India, delaying their reaching the poor&lt;/em&gt;&lt;/p&gt;&lt;p align=&quot;justify&quot;&gt;&amp;nbsp;&lt;/p&gt;&lt;p align=&quot;justify&quot;&gt;The battle for affordable, life-saving medicines for poor countries was once waged on first-world city streets with banners and placards. But for some years now it has been a long-hard legal slog in offices and courtrooms.&lt;/p&gt;&lt;p align=&quot;justify&quot;&gt;A decade or so ago, it was mostly about access to Aids drugs. Firms that made the drugs at prices too high for all but citizens of the rich world were shamed and left on the back foot by campaigners in the US and Europe.&lt;/p&gt;&lt;p align=&quot;justify&quot;&gt;The activists won some famous victories, breaking the patent stranglehold of the big firms and enabling the sale of cheap generic copies. Millions of people with HIV are alive and leading normal lives in poor countries as a result.&lt;/p&gt;&lt;p align=&quot;justify&quot;&gt;The multinational drug companies, however, have been working hard to prevent further erosion of their profits by generic, copycat manufacturers whom they once openly called pirates.&lt;/p&gt;&lt;p align=&quot;justify&quot;&gt;The companies, with support from the US and European governments which want a profitable drug industry, they have worked to tighten patent protection for new drugs through national laws and trade agreements. India has been the main focus in its historical role as the pharmacy of the developing world.&lt;/p&gt;&lt;p align=&quot;justify&quot;&gt;Under the World Trade Organisation&#039;s trade-related intellectual property rights (Trips) rules, India agreed to bring in patents for drugs in 2005. Drugs without patent protection before that date can still be copied and sold cheaply to developing countries by generics companies.&lt;/p&gt;&lt;p align=&quot;justify&quot;&gt;Novartis began seeking patent protection for its cancer drug Glivec as soon as the law came into force, but as the drug was already on the market the Swiss firm could not make a standard application. Instead, it sought a patent for a slightly altered version that it said was easier for patients to absorb. Novartis argued that this was innovation under Indian law and deserving of a patent.&lt;/p&gt;&lt;p align=&quot;justify&quot;&gt;The stakes were high. Glivec costs around &amp;pound;1,700 a month. Indian generic copies cost around &amp;pound;115.&lt;/p&gt;&lt;p align=&quot;justify&quot;&gt;Campaigners, already concerned that the Indian patent law would delay important new medicines reaching the poor, could see that if Novartis won its legal case, the &amp;quot;evergreening&amp;quot; of drugs by other companies would become routine. Patents usually expire after 20 years, meaning it could be decades more before prices would drop.&lt;/p&gt;&lt;p align=&quot;justify&quot;&gt;&amp;quot;Had the Novartis case been successful, it definitely would have extended massively the ability to patent other medicines within India,&amp;quot; said Jennifer Cohn, the medical director for M&amp;eacute;decins Sans Fronti&amp;egrave;res&#039; access campaign.&lt;/p&gt;&lt;p align=&quot;justify&quot;&gt;It is an important victory, say the campaigners, but they still feel embattled. New classes of HIV drugs are being patented now in India and will not reach Africa for many years as a result, Cohn said. The same is true of new tuberculosis and hepatitis C drugs.&lt;/p&gt;&lt;p align=&quot;justify&quot;&gt;Campaigners also worry about trade agreements such as the Trans-Pacific Partnership, which is being negotiated between Australia, Canada, the US, Malaysia, Chile, Mexico, Peru, Vietnam and others, and require stringent patent protection.&lt;/p&gt;&lt;p align=&quot;justify&quot;&gt;The companies and their supporters, however, argue strongly that without the financial reward that long-lasting patents offer, they will not have incentives to develop new medicines. They also threaten to boycott countries that will not allow them a monopoly on their own drugs.&lt;/p&gt;&lt;p align=&quot;justify&quot;&gt;No one thinks there are any simple solutions.&lt;/p&gt;&#039;
$lang = &#039;English&#039;
$SITE_URL = &#039;https://im4change.in/&#039;
$site_title = &#039;im4change&#039;
$adminprix = &#039;admin&#039;</pre><pre class="stack-trace">include - APP/Template/Layout/printlayout.ctp, line 8
Cake\View\View::_evaluate() - CORE/src/View/View.php, line 1413
Cake\View\View::_render() - CORE/src/View/View.php, line 1374
Cake\View\View::renderLayout() - CORE/src/View/View.php, line 927
Cake\View\View::render() - CORE/src/View/View.php, line 885
Cake\Controller\Controller::render() - CORE/src/Controller/Controller.php, line 791
Cake\Http\ActionDispatcher::_invoke() - CORE/src/Http/ActionDispatcher.php, line 126
Cake\Http\ActionDispatcher::dispatch() - CORE/src/Http/ActionDispatcher.php, line 94
Cake\Http\BaseApplication::__invoke() - CORE/src/Http/BaseApplication.php, line 235
Cake\Http\Runner::__invoke() - CORE/src/Http/Runner.php, line 65
Cake\Routing\Middleware\RoutingMiddleware::__invoke() - CORE/src/Routing/Middleware/RoutingMiddleware.php, line 162
Cake\Http\Runner::__invoke() - CORE/src/Http/Runner.php, line 65
Cake\Routing\Middleware\AssetMiddleware::__invoke() - CORE/src/Routing/Middleware/AssetMiddleware.php, line 88
Cake\Http\Runner::__invoke() - CORE/src/Http/Runner.php, line 65
Cake\Error\Middleware\ErrorHandlerMiddleware::__invoke() - CORE/src/Error/Middleware/ErrorHandlerMiddleware.php, line 96
Cake\Http\Runner::__invoke() - CORE/src/Http/Runner.php, line 65
Cake\Http\Runner::run() - CORE/src/Http/Runner.php, line 51</pre></div></pre>latest-news-updates/novartis-patent-ruling-a-victory-in-battle-for-affordable-medicines-sarah-boseley-20308.html"/>
    <meta http-equiv="Content-Type" content="text/html; charset=utf-8"/>
    <link href="https://im4change.in/css/control.css" rel="stylesheet" type="text/css"
          media="all"/>
    <title>LATEST NEWS UPDATES | Novartis patent ruling a victory in battle for affordable medicines-Sarah Boseley | Im4change.org</title>
    <meta name="description" content="
-The Guardian



Had Novartis won, it would have set a precedent for patenting of other medicines in India, delaying their reaching the poor


&nbsp;


The battle for affordable, life-saving medicines for poor countries was once waged on first-world city streets with banners and..."/>
    <script src="https://im4change.in/js/jquery-1.10.2.js"></script>
    <script type="text/javascript" src="https://im4change.in/js/jquery-migrate.min.js"></script>
    <script language="javascript" type="text/javascript">

        $(document).ready(function () {
            var img = $("img")[0]; // Get my img elem
            var pic_real_width, pic_real_height;
            $("<img/>") // Make in memory copy of image to avoid css issues
                .attr("src", $(img).attr("src"))
                .load(function () {
                    pic_real_width = this.width;   // Note: $(this).width() will not
                    pic_real_height = this.height; // work for in memory images.
                });
        });
    </script>
    <style type="text/css">
        @media screen {
            div.divFooter {
                display: block;
            }
        }

        @media print {
            .printbutton {
                display: none !important;
            }
        }
    </style>
</head>
<body>
<table cellpadding="0" cellspacing="0" border="0" width="98%" align="center">
    <tr>
        <td class="top_bg">
            <div class="divFooter">
                <img src="https://im4change.in/images/logo1.jpg" height="59" border="0"
                     alt="Resource centre on India's rural distress" style="padding-top:14px;"/>
            </div>

        </td>
    </tr>
    <tr>
        <td id="topspace">&nbsp;</td>
    </tr>

    <tr id="topspace">
        <td>&nbsp;</td>
    </tr>
    <tr>
        <td height="50" style="border-bottom:1px solid #000; padding-top:10px;" class="printbutton">
            <form><input type="button" value=" Print this page "
                         onclick="window.print();return false;"/></form>
        </td>
    </tr>

    <tr>
        <td width="100%">
            <h1 class="news_headlines" style="font-style:normal">
                <strong>Novartis patent ruling a victory in battle for affordable medicines-Sarah Boseley</strong></h1>
        </td>
    </tr>
    <tr>
        <td width="100%" style="font-family:Arial, 'Segoe Script', 'Segoe UI', sans-serif, serif"><font size="3">
                <div align="justify">-The Guardian</div><p align="justify"><br /><em>Had Novartis won, it would have set a precedent for patenting of other medicines in India, delaying their reaching the poor</em></p><p align="justify">&nbsp;</p><p align="justify">The battle for affordable, life-saving medicines for poor countries was once waged on first-world city streets with banners and placards. But for some years now it has been a long-hard legal slog in offices and courtrooms.</p><p align="justify">A decade or so ago, it was mostly about access to Aids drugs. Firms that made the drugs at prices too high for all but citizens of the rich world were shamed and left on the back foot by campaigners in the US and Europe.</p><p align="justify">The activists won some famous victories, breaking the patent stranglehold of the big firms and enabling the sale of cheap generic copies. Millions of people with HIV are alive and leading normal lives in poor countries as a result.</p><p align="justify">The multinational drug companies, however, have been working hard to prevent further erosion of their profits by generic, copycat manufacturers whom they once openly called pirates.</p><p align="justify">The companies, with support from the US and European governments which want a profitable drug industry, they have worked to tighten patent protection for new drugs through national laws and trade agreements. India has been the main focus in its historical role as the pharmacy of the developing world.</p><p align="justify">Under the World Trade Organisation's trade-related intellectual property rights (Trips) rules, India agreed to bring in patents for drugs in 2005. Drugs without patent protection before that date can still be copied and sold cheaply to developing countries by generics companies.</p><p align="justify">Novartis began seeking patent protection for its cancer drug Glivec as soon as the law came into force, but as the drug was already on the market the Swiss firm could not make a standard application. Instead, it sought a patent for a slightly altered version that it said was easier for patients to absorb. Novartis argued that this was innovation under Indian law and deserving of a patent.</p><p align="justify">The stakes were high. Glivec costs around &pound;1,700 a month. Indian generic copies cost around &pound;115.</p><p align="justify">Campaigners, already concerned that the Indian patent law would delay important new medicines reaching the poor, could see that if Novartis won its legal case, the &quot;evergreening&quot; of drugs by other companies would become routine. Patents usually expire after 20 years, meaning it could be decades more before prices would drop.</p><p align="justify">&quot;Had the Novartis case been successful, it definitely would have extended massively the ability to patent other medicines within India,&quot; said Jennifer Cohn, the medical director for M&eacute;decins Sans Fronti&egrave;res' access campaign.</p><p align="justify">It is an important victory, say the campaigners, but they still feel embattled. New classes of HIV drugs are being patented now in India and will not reach Africa for many years as a result, Cohn said. The same is true of new tuberculosis and hepatitis C drugs.</p><p align="justify">Campaigners also worry about trade agreements such as the Trans-Pacific Partnership, which is being negotiated between Australia, Canada, the US, Malaysia, Chile, Mexico, Peru, Vietnam and others, and require stringent patent protection.</p><p align="justify">The companies and their supporters, however, argue strongly that without the financial reward that long-lasting patents offer, they will not have incentives to develop new medicines. They also threaten to boycott countries that will not allow them a monopoly on their own drugs.</p><p align="justify">No one thinks there are any simple solutions.</p>               </font>
        </td>
    </tr>
    <tr>
        <td>&nbsp;</td>
    </tr>

    <tr>
        <td height="50" style="border-top:1px solid #000; border-bottom:1px solid #000;padding-top:10px;">
            <form><input type="button" value=" Print this page "
                         onclick="window.print();return false;"/></form>
        </td>
    </tr>
</table></body>
</html>'

}
$reasonPhrase = 'OK'
header - [internal], line ??
Cake\Http\ResponseEmitter::emitStatusLine() - CORE/src/Http/ResponseEmitter.php, line 148
Cake\Http\ResponseEmitter::emit() - CORE/src/Http/ResponseEmitter.php, line 54
Cake\Http\Server::emit() - CORE/src/Http/Server.php, line 141
[main] - ROOT/webroot/index.php, line 39

Warning (2): Cannot modify header information - headers already sent by (output started at /home/brlfuser/public_html/vendor/cakephp/cakephp/src/Error/Debugger.php:853) [CORE/src/Http/ResponseEmitter.php, line 181]
Code Context
                    $value

                ), $first);

                $first = false;
$response = object(Cake\Http\Response) {

	'status' => (int) 200,
	'contentType' => 'text/html',
	'headers' => [
		'Content-Type' => [
			[maximum depth reached]
		]
	],
	'file' => null,
	'fileRange' => [],
	'cookies' => object(Cake\Http\Cookie\CookieCollection) {},
	'cacheDirectives' => [],
	'body' => '<!DOCTYPE html PUBLIC "-//W3C//DTD XHTML 1.0 Transitional//EN"
        "http://www.w3.org/TR/xhtml1/DTD/xhtml1-transitional.dtd">
<html xmlns="http://www.w3.org/1999/xhtml">
<head>
    <link rel="canonical" href="https://im4change.in/<pre class="cake-error"><a href="javascript:void(0);" onclick="document.getElementById('cakeErr67f07d8435f7e-trace').style.display = (document.getElementById('cakeErr67f07d8435f7e-trace').style.display == 'none' ? '' : 'none');"><b>Notice</b> (8)</a>: Undefined variable: urlPrefix [<b>APP/Template/Layout/printlayout.ctp</b>, line <b>8</b>]<div id="cakeErr67f07d8435f7e-trace" class="cake-stack-trace" style="display: none;"><a href="javascript:void(0);" onclick="document.getElementById('cakeErr67f07d8435f7e-code').style.display = (document.getElementById('cakeErr67f07d8435f7e-code').style.display == 'none' ? '' : 'none')">Code</a> <a href="javascript:void(0);" onclick="document.getElementById('cakeErr67f07d8435f7e-context').style.display = (document.getElementById('cakeErr67f07d8435f7e-context').style.display == 'none' ? '' : 'none')">Context</a><pre id="cakeErr67f07d8435f7e-code" class="cake-code-dump" style="display: none;"><code><span style="color: #000000"><span style="color: #0000BB"></span><span style="color: #007700">&lt;</span><span style="color: #0000BB">head</span><span style="color: #007700">&gt;
</span></span></code>
<span class="code-highlight"><code><span style="color: #000000">&nbsp;&nbsp;&nbsp;&nbsp;&lt;link&nbsp;rel="canonical"&nbsp;href="<span style="color: #0000BB">&lt;?php&nbsp;</span><span style="color: #007700">echo&nbsp;</span><span style="color: #0000BB">Configure</span><span style="color: #007700">::</span><span style="color: #0000BB">read</span><span style="color: #007700">(</span><span style="color: #DD0000">'SITE_URL'</span><span style="color: #007700">);&nbsp;</span><span style="color: #0000BB">?&gt;&lt;?php&nbsp;</span><span style="color: #007700">echo&nbsp;</span><span style="color: #0000BB">$urlPrefix</span><span style="color: #007700">;</span><span style="color: #0000BB">?&gt;&lt;?php&nbsp;</span><span style="color: #007700">echo&nbsp;</span><span style="color: #0000BB">$article_current</span><span style="color: #007700">-&gt;</span><span style="color: #0000BB">category</span><span style="color: #007700">-&gt;</span><span style="color: #0000BB">slug</span><span style="color: #007700">;&nbsp;</span><span style="color: #0000BB">?&gt;</span>/<span style="color: #0000BB">&lt;?php&nbsp;</span><span style="color: #007700">echo&nbsp;</span><span style="color: #0000BB">$article_current</span><span style="color: #007700">-&gt;</span><span style="color: #0000BB">seo_url</span><span style="color: #007700">;&nbsp;</span><span style="color: #0000BB">?&gt;</span>.html"/&gt;
</span></code></span>
<code><span style="color: #000000"><span style="color: #0000BB">&nbsp;&nbsp;&nbsp;&nbsp;</span><span style="color: #007700">&lt;</span><span style="color: #0000BB">meta&nbsp;http</span><span style="color: #007700">-</span><span style="color: #0000BB">equiv</span><span style="color: #007700">=</span><span style="color: #DD0000">"Content-Type"&nbsp;</span><span style="color: #0000BB">content</span><span style="color: #007700">=</span><span style="color: #DD0000">"text/html;&nbsp;charset=utf-8"</span><span style="color: #007700">/&gt;
</span></span></code></pre><pre id="cakeErr67f07d8435f7e-context" class="cake-context" style="display: none;">$viewFile = &#039;/home/brlfuser/public_html/src/Template/Layout/printlayout.ctp&#039;
$dataForView = [
	&#039;article_current&#039; =&gt; object(App\Model\Entity\Article) {

		&#039;id&#039; =&gt; (int) 20167,
		&#039;title&#039; =&gt; &#039;Novartis patent ruling a victory in battle for affordable medicines-Sarah Boseley&#039;,
		&#039;subheading&#039; =&gt; &#039;&#039;,
		&#039;description&#039; =&gt; &#039;&lt;div align=&quot;justify&quot;&gt;
-The Guardian
&lt;/div&gt;
&lt;p align=&quot;justify&quot;&gt;
&lt;br /&gt;
&lt;em&gt;Had Novartis won, it would have set a precedent for patenting of other medicines in India, delaying their reaching the poor&lt;/em&gt;
&lt;/p&gt;
&lt;p align=&quot;justify&quot;&gt;
&amp;nbsp;
&lt;/p&gt;
&lt;p align=&quot;justify&quot;&gt;
The battle for affordable, life-saving medicines for poor countries was once waged on first-world city streets with banners and placards. But for some years now it has been a long-hard legal slog in offices and courtrooms.
&lt;/p&gt;
&lt;p align=&quot;justify&quot;&gt;
A decade or so ago, it was mostly about access to Aids drugs. Firms that made the drugs at prices too high for all but citizens of the rich world were shamed and left on the back foot by campaigners in the US and Europe.
&lt;/p&gt;
&lt;p align=&quot;justify&quot;&gt;
The activists won some famous victories, breaking the patent stranglehold of the big firms and enabling the sale of cheap generic copies. Millions of people with HIV are alive and leading normal lives in poor countries as a result.
&lt;/p&gt;
&lt;p align=&quot;justify&quot;&gt;
The multinational drug companies, however, have been working hard to prevent further erosion of their profits by generic, copycat manufacturers whom they once openly called pirates.
&lt;/p&gt;
&lt;p align=&quot;justify&quot;&gt;
The companies, with support from the US and European governments which want a profitable drug industry, they have worked to tighten patent protection for new drugs through national laws and trade agreements. India has been the main focus in its historical role as the pharmacy of the developing world.
&lt;/p&gt;
&lt;p align=&quot;justify&quot;&gt;
Under the World Trade Organisation&#039;s trade-related intellectual property rights (Trips) rules, India agreed to bring in patents for drugs in 2005. Drugs without patent protection before that date can still be copied and sold cheaply to developing countries by generics companies.
&lt;/p&gt;
&lt;p align=&quot;justify&quot;&gt;
Novartis began seeking patent protection for its cancer drug Glivec as soon as the law came into force, but as the drug was already on the market the Swiss firm could not make a standard application. Instead, it sought a patent for a slightly altered version that it said was easier for patients to absorb. Novartis argued that this was innovation under Indian law and deserving of a patent.
&lt;/p&gt;
&lt;p align=&quot;justify&quot;&gt;
The stakes were high. Glivec costs around &amp;pound;1,700 a month. Indian generic copies cost around &amp;pound;115.
&lt;/p&gt;
&lt;p align=&quot;justify&quot;&gt;
Campaigners, already concerned that the Indian patent law would delay important new medicines reaching the poor, could see that if Novartis won its legal case, the &amp;quot;evergreening&amp;quot; of drugs by other companies would become routine. Patents usually expire after 20 years, meaning it could be decades more before prices would drop.
&lt;/p&gt;
&lt;p align=&quot;justify&quot;&gt;
&amp;quot;Had the Novartis case been successful, it definitely would have extended massively the ability to patent other medicines within India,&amp;quot; said Jennifer Cohn, the medical director for M&amp;eacute;decins Sans Fronti&amp;egrave;res&#039; access campaign.
&lt;/p&gt;
&lt;p align=&quot;justify&quot;&gt;
It is an important victory, say the campaigners, but they still feel embattled. New classes of HIV drugs are being patented now in India and will not reach Africa for many years as a result, Cohn said. The same is true of new tuberculosis and hepatitis C drugs.
&lt;/p&gt;
&lt;p align=&quot;justify&quot;&gt;
Campaigners also worry about trade agreements such as the Trans-Pacific Partnership, which is being negotiated between Australia, Canada, the US, Malaysia, Chile, Mexico, Peru, Vietnam and others, and require stringent patent protection.
&lt;/p&gt;
&lt;p align=&quot;justify&quot;&gt;
The companies and their supporters, however, argue strongly that without the financial reward that long-lasting patents offer, they will not have incentives to develop new medicines. They also threaten to boycott countries that will not allow them a monopoly on their own drugs.
&lt;/p&gt;
&lt;p align=&quot;justify&quot;&gt;
No one thinks there are any simple solutions.
&lt;/p&gt;&#039;,
		&#039;credit_writer&#039; =&gt; &#039;The Guardian, 1 April, 2013, http://www.guardian.co.uk/world/2013/apr/01/novartis-patent-ruling-affordable-medicines&#039;,
		&#039;article_img&#039; =&gt; &#039;&#039;,
		&#039;article_img_thumb&#039; =&gt; &#039;&#039;,
		&#039;status&#039; =&gt; (int) 1,
		&#039;show_on_home&#039; =&gt; (int) 1,
		&#039;lang&#039; =&gt; &#039;EN&#039;,
		&#039;category_id&#039; =&gt; (int) 16,
		&#039;tag_keyword&#039; =&gt; &#039;&#039;,
		&#039;seo_url&#039; =&gt; &#039;novartis-patent-ruling-a-victory-in-battle-for-affordable-medicines-sarah-boseley-20308&#039;,
		&#039;meta_title&#039; =&gt; null,
		&#039;meta_keywords&#039; =&gt; null,
		&#039;meta_description&#039; =&gt; null,
		&#039;noindex&#039; =&gt; (int) 0,
		&#039;publish_date&#039; =&gt; object(Cake\I18n\FrozenDate) {},
		&#039;most_visit_section_id&#039; =&gt; null,
		&#039;article_big_img&#039; =&gt; null,
		&#039;liveid&#039; =&gt; (int) 20308,
		&#039;created&#039; =&gt; object(Cake\I18n\FrozenTime) {},
		&#039;modified&#039; =&gt; object(Cake\I18n\FrozenTime) {},
		&#039;edate&#039; =&gt; &#039;&#039;,
		&#039;tags&#039; =&gt; [
			[maximum depth reached]
		],
		&#039;category&#039; =&gt; object(App\Model\Entity\Category) {},
		&#039;[new]&#039; =&gt; false,
		&#039;[accessible]&#039; =&gt; [
			[maximum depth reached]
		],
		&#039;[dirty]&#039; =&gt; [[maximum depth reached]],
		&#039;[original]&#039; =&gt; [[maximum depth reached]],
		&#039;[virtual]&#039; =&gt; [[maximum depth reached]],
		&#039;[hasErrors]&#039; =&gt; false,
		&#039;[errors]&#039; =&gt; [[maximum depth reached]],
		&#039;[invalid]&#039; =&gt; [[maximum depth reached]],
		&#039;[repository]&#039; =&gt; &#039;Articles&#039;
	
	},
	&#039;articleid&#039; =&gt; (int) 20167,
	&#039;metaTitle&#039; =&gt; &#039;LATEST NEWS UPDATES | Novartis patent ruling a victory in battle for affordable medicines-Sarah Boseley&#039;,
	&#039;metaKeywords&#039; =&gt; &#039;novartis,generic drugs,patents,medicines&#039;,
	&#039;metaDesc&#039; =&gt; &#039;
-The Guardian



Had Novartis won, it would have set a precedent for patenting of other medicines in India, delaying their reaching the poor


&amp;nbsp;


The battle for affordable, life-saving medicines for poor countries was once waged on first-world city streets with banners and...&#039;,
	&#039;disp&#039; =&gt; &#039;&lt;div align=&quot;justify&quot;&gt;-The Guardian&lt;/div&gt;&lt;p align=&quot;justify&quot;&gt;&lt;br /&gt;&lt;em&gt;Had Novartis won, it would have set a precedent for patenting of other medicines in India, delaying their reaching the poor&lt;/em&gt;&lt;/p&gt;&lt;p align=&quot;justify&quot;&gt;&amp;nbsp;&lt;/p&gt;&lt;p align=&quot;justify&quot;&gt;The battle for affordable, life-saving medicines for poor countries was once waged on first-world city streets with banners and placards. But for some years now it has been a long-hard legal slog in offices and courtrooms.&lt;/p&gt;&lt;p align=&quot;justify&quot;&gt;A decade or so ago, it was mostly about access to Aids drugs. Firms that made the drugs at prices too high for all but citizens of the rich world were shamed and left on the back foot by campaigners in the US and Europe.&lt;/p&gt;&lt;p align=&quot;justify&quot;&gt;The activists won some famous victories, breaking the patent stranglehold of the big firms and enabling the sale of cheap generic copies. Millions of people with HIV are alive and leading normal lives in poor countries as a result.&lt;/p&gt;&lt;p align=&quot;justify&quot;&gt;The multinational drug companies, however, have been working hard to prevent further erosion of their profits by generic, copycat manufacturers whom they once openly called pirates.&lt;/p&gt;&lt;p align=&quot;justify&quot;&gt;The companies, with support from the US and European governments which want a profitable drug industry, they have worked to tighten patent protection for new drugs through national laws and trade agreements. India has been the main focus in its historical role as the pharmacy of the developing world.&lt;/p&gt;&lt;p align=&quot;justify&quot;&gt;Under the World Trade Organisation&#039;s trade-related intellectual property rights (Trips) rules, India agreed to bring in patents for drugs in 2005. Drugs without patent protection before that date can still be copied and sold cheaply to developing countries by generics companies.&lt;/p&gt;&lt;p align=&quot;justify&quot;&gt;Novartis began seeking patent protection for its cancer drug Glivec as soon as the law came into force, but as the drug was already on the market the Swiss firm could not make a standard application. Instead, it sought a patent for a slightly altered version that it said was easier for patients to absorb. Novartis argued that this was innovation under Indian law and deserving of a patent.&lt;/p&gt;&lt;p align=&quot;justify&quot;&gt;The stakes were high. Glivec costs around &amp;pound;1,700 a month. Indian generic copies cost around &amp;pound;115.&lt;/p&gt;&lt;p align=&quot;justify&quot;&gt;Campaigners, already concerned that the Indian patent law would delay important new medicines reaching the poor, could see that if Novartis won its legal case, the &amp;quot;evergreening&amp;quot; of drugs by other companies would become routine. Patents usually expire after 20 years, meaning it could be decades more before prices would drop.&lt;/p&gt;&lt;p align=&quot;justify&quot;&gt;&amp;quot;Had the Novartis case been successful, it definitely would have extended massively the ability to patent other medicines within India,&amp;quot; said Jennifer Cohn, the medical director for M&amp;eacute;decins Sans Fronti&amp;egrave;res&#039; access campaign.&lt;/p&gt;&lt;p align=&quot;justify&quot;&gt;It is an important victory, say the campaigners, but they still feel embattled. New classes of HIV drugs are being patented now in India and will not reach Africa for many years as a result, Cohn said. The same is true of new tuberculosis and hepatitis C drugs.&lt;/p&gt;&lt;p align=&quot;justify&quot;&gt;Campaigners also worry about trade agreements such as the Trans-Pacific Partnership, which is being negotiated between Australia, Canada, the US, Malaysia, Chile, Mexico, Peru, Vietnam and others, and require stringent patent protection.&lt;/p&gt;&lt;p align=&quot;justify&quot;&gt;The companies and their supporters, however, argue strongly that without the financial reward that long-lasting patents offer, they will not have incentives to develop new medicines. They also threaten to boycott countries that will not allow them a monopoly on their own drugs.&lt;/p&gt;&lt;p align=&quot;justify&quot;&gt;No one thinks there are any simple solutions.&lt;/p&gt;&#039;,
	&#039;lang&#039; =&gt; &#039;English&#039;,
	&#039;SITE_URL&#039; =&gt; &#039;https://im4change.in/&#039;,
	&#039;site_title&#039; =&gt; &#039;im4change&#039;,
	&#039;adminprix&#039; =&gt; &#039;admin&#039;
]
$article_current = object(App\Model\Entity\Article) {

	&#039;id&#039; =&gt; (int) 20167,
	&#039;title&#039; =&gt; &#039;Novartis patent ruling a victory in battle for affordable medicines-Sarah Boseley&#039;,
	&#039;subheading&#039; =&gt; &#039;&#039;,
	&#039;description&#039; =&gt; &#039;&lt;div align=&quot;justify&quot;&gt;
-The Guardian
&lt;/div&gt;
&lt;p align=&quot;justify&quot;&gt;
&lt;br /&gt;
&lt;em&gt;Had Novartis won, it would have set a precedent for patenting of other medicines in India, delaying their reaching the poor&lt;/em&gt;
&lt;/p&gt;
&lt;p align=&quot;justify&quot;&gt;
&amp;nbsp;
&lt;/p&gt;
&lt;p align=&quot;justify&quot;&gt;
The battle for affordable, life-saving medicines for poor countries was once waged on first-world city streets with banners and placards. But for some years now it has been a long-hard legal slog in offices and courtrooms.
&lt;/p&gt;
&lt;p align=&quot;justify&quot;&gt;
A decade or so ago, it was mostly about access to Aids drugs. Firms that made the drugs at prices too high for all but citizens of the rich world were shamed and left on the back foot by campaigners in the US and Europe.
&lt;/p&gt;
&lt;p align=&quot;justify&quot;&gt;
The activists won some famous victories, breaking the patent stranglehold of the big firms and enabling the sale of cheap generic copies. Millions of people with HIV are alive and leading normal lives in poor countries as a result.
&lt;/p&gt;
&lt;p align=&quot;justify&quot;&gt;
The multinational drug companies, however, have been working hard to prevent further erosion of their profits by generic, copycat manufacturers whom they once openly called pirates.
&lt;/p&gt;
&lt;p align=&quot;justify&quot;&gt;
The companies, with support from the US and European governments which want a profitable drug industry, they have worked to tighten patent protection for new drugs through national laws and trade agreements. India has been the main focus in its historical role as the pharmacy of the developing world.
&lt;/p&gt;
&lt;p align=&quot;justify&quot;&gt;
Under the World Trade Organisation&#039;s trade-related intellectual property rights (Trips) rules, India agreed to bring in patents for drugs in 2005. Drugs without patent protection before that date can still be copied and sold cheaply to developing countries by generics companies.
&lt;/p&gt;
&lt;p align=&quot;justify&quot;&gt;
Novartis began seeking patent protection for its cancer drug Glivec as soon as the law came into force, but as the drug was already on the market the Swiss firm could not make a standard application. Instead, it sought a patent for a slightly altered version that it said was easier for patients to absorb. Novartis argued that this was innovation under Indian law and deserving of a patent.
&lt;/p&gt;
&lt;p align=&quot;justify&quot;&gt;
The stakes were high. Glivec costs around &amp;pound;1,700 a month. Indian generic copies cost around &amp;pound;115.
&lt;/p&gt;
&lt;p align=&quot;justify&quot;&gt;
Campaigners, already concerned that the Indian patent law would delay important new medicines reaching the poor, could see that if Novartis won its legal case, the &amp;quot;evergreening&amp;quot; of drugs by other companies would become routine. Patents usually expire after 20 years, meaning it could be decades more before prices would drop.
&lt;/p&gt;
&lt;p align=&quot;justify&quot;&gt;
&amp;quot;Had the Novartis case been successful, it definitely would have extended massively the ability to patent other medicines within India,&amp;quot; said Jennifer Cohn, the medical director for M&amp;eacute;decins Sans Fronti&amp;egrave;res&#039; access campaign.
&lt;/p&gt;
&lt;p align=&quot;justify&quot;&gt;
It is an important victory, say the campaigners, but they still feel embattled. New classes of HIV drugs are being patented now in India and will not reach Africa for many years as a result, Cohn said. The same is true of new tuberculosis and hepatitis C drugs.
&lt;/p&gt;
&lt;p align=&quot;justify&quot;&gt;
Campaigners also worry about trade agreements such as the Trans-Pacific Partnership, which is being negotiated between Australia, Canada, the US, Malaysia, Chile, Mexico, Peru, Vietnam and others, and require stringent patent protection.
&lt;/p&gt;
&lt;p align=&quot;justify&quot;&gt;
The companies and their supporters, however, argue strongly that without the financial reward that long-lasting patents offer, they will not have incentives to develop new medicines. They also threaten to boycott countries that will not allow them a monopoly on their own drugs.
&lt;/p&gt;
&lt;p align=&quot;justify&quot;&gt;
No one thinks there are any simple solutions.
&lt;/p&gt;&#039;,
	&#039;credit_writer&#039; =&gt; &#039;The Guardian, 1 April, 2013, http://www.guardian.co.uk/world/2013/apr/01/novartis-patent-ruling-affordable-medicines&#039;,
	&#039;article_img&#039; =&gt; &#039;&#039;,
	&#039;article_img_thumb&#039; =&gt; &#039;&#039;,
	&#039;status&#039; =&gt; (int) 1,
	&#039;show_on_home&#039; =&gt; (int) 1,
	&#039;lang&#039; =&gt; &#039;EN&#039;,
	&#039;category_id&#039; =&gt; (int) 16,
	&#039;tag_keyword&#039; =&gt; &#039;&#039;,
	&#039;seo_url&#039; =&gt; &#039;novartis-patent-ruling-a-victory-in-battle-for-affordable-medicines-sarah-boseley-20308&#039;,
	&#039;meta_title&#039; =&gt; null,
	&#039;meta_keywords&#039; =&gt; null,
	&#039;meta_description&#039; =&gt; null,
	&#039;noindex&#039; =&gt; (int) 0,
	&#039;publish_date&#039; =&gt; object(Cake\I18n\FrozenDate) {},
	&#039;most_visit_section_id&#039; =&gt; null,
	&#039;article_big_img&#039; =&gt; null,
	&#039;liveid&#039; =&gt; (int) 20308,
	&#039;created&#039; =&gt; object(Cake\I18n\FrozenTime) {},
	&#039;modified&#039; =&gt; object(Cake\I18n\FrozenTime) {},
	&#039;edate&#039; =&gt; &#039;&#039;,
	&#039;tags&#039; =&gt; [
		(int) 0 =&gt; object(Cake\ORM\Entity) {},
		(int) 1 =&gt; object(Cake\ORM\Entity) {},
		(int) 2 =&gt; object(Cake\ORM\Entity) {},
		(int) 3 =&gt; object(Cake\ORM\Entity) {}
	],
	&#039;category&#039; =&gt; object(App\Model\Entity\Category) {},
	&#039;[new]&#039; =&gt; false,
	&#039;[accessible]&#039; =&gt; [
		&#039;*&#039; =&gt; true,
		&#039;id&#039; =&gt; false
	],
	&#039;[dirty]&#039; =&gt; [],
	&#039;[original]&#039; =&gt; [],
	&#039;[virtual]&#039; =&gt; [],
	&#039;[hasErrors]&#039; =&gt; false,
	&#039;[errors]&#039; =&gt; [],
	&#039;[invalid]&#039; =&gt; [],
	&#039;[repository]&#039; =&gt; &#039;Articles&#039;

}
$articleid = (int) 20167
$metaTitle = &#039;LATEST NEWS UPDATES | Novartis patent ruling a victory in battle for affordable medicines-Sarah Boseley&#039;
$metaKeywords = &#039;novartis,generic drugs,patents,medicines&#039;
$metaDesc = &#039;
-The Guardian



Had Novartis won, it would have set a precedent for patenting of other medicines in India, delaying their reaching the poor


&amp;nbsp;


The battle for affordable, life-saving medicines for poor countries was once waged on first-world city streets with banners and...&#039;
$disp = &#039;&lt;div align=&quot;justify&quot;&gt;-The Guardian&lt;/div&gt;&lt;p align=&quot;justify&quot;&gt;&lt;br /&gt;&lt;em&gt;Had Novartis won, it would have set a precedent for patenting of other medicines in India, delaying their reaching the poor&lt;/em&gt;&lt;/p&gt;&lt;p align=&quot;justify&quot;&gt;&amp;nbsp;&lt;/p&gt;&lt;p align=&quot;justify&quot;&gt;The battle for affordable, life-saving medicines for poor countries was once waged on first-world city streets with banners and placards. But for some years now it has been a long-hard legal slog in offices and courtrooms.&lt;/p&gt;&lt;p align=&quot;justify&quot;&gt;A decade or so ago, it was mostly about access to Aids drugs. Firms that made the drugs at prices too high for all but citizens of the rich world were shamed and left on the back foot by campaigners in the US and Europe.&lt;/p&gt;&lt;p align=&quot;justify&quot;&gt;The activists won some famous victories, breaking the patent stranglehold of the big firms and enabling the sale of cheap generic copies. Millions of people with HIV are alive and leading normal lives in poor countries as a result.&lt;/p&gt;&lt;p align=&quot;justify&quot;&gt;The multinational drug companies, however, have been working hard to prevent further erosion of their profits by generic, copycat manufacturers whom they once openly called pirates.&lt;/p&gt;&lt;p align=&quot;justify&quot;&gt;The companies, with support from the US and European governments which want a profitable drug industry, they have worked to tighten patent protection for new drugs through national laws and trade agreements. India has been the main focus in its historical role as the pharmacy of the developing world.&lt;/p&gt;&lt;p align=&quot;justify&quot;&gt;Under the World Trade Organisation&#039;s trade-related intellectual property rights (Trips) rules, India agreed to bring in patents for drugs in 2005. Drugs without patent protection before that date can still be copied and sold cheaply to developing countries by generics companies.&lt;/p&gt;&lt;p align=&quot;justify&quot;&gt;Novartis began seeking patent protection for its cancer drug Glivec as soon as the law came into force, but as the drug was already on the market the Swiss firm could not make a standard application. Instead, it sought a patent for a slightly altered version that it said was easier for patients to absorb. Novartis argued that this was innovation under Indian law and deserving of a patent.&lt;/p&gt;&lt;p align=&quot;justify&quot;&gt;The stakes were high. Glivec costs around &amp;pound;1,700 a month. Indian generic copies cost around &amp;pound;115.&lt;/p&gt;&lt;p align=&quot;justify&quot;&gt;Campaigners, already concerned that the Indian patent law would delay important new medicines reaching the poor, could see that if Novartis won its legal case, the &amp;quot;evergreening&amp;quot; of drugs by other companies would become routine. Patents usually expire after 20 years, meaning it could be decades more before prices would drop.&lt;/p&gt;&lt;p align=&quot;justify&quot;&gt;&amp;quot;Had the Novartis case been successful, it definitely would have extended massively the ability to patent other medicines within India,&amp;quot; said Jennifer Cohn, the medical director for M&amp;eacute;decins Sans Fronti&amp;egrave;res&#039; access campaign.&lt;/p&gt;&lt;p align=&quot;justify&quot;&gt;It is an important victory, say the campaigners, but they still feel embattled. New classes of HIV drugs are being patented now in India and will not reach Africa for many years as a result, Cohn said. The same is true of new tuberculosis and hepatitis C drugs.&lt;/p&gt;&lt;p align=&quot;justify&quot;&gt;Campaigners also worry about trade agreements such as the Trans-Pacific Partnership, which is being negotiated between Australia, Canada, the US, Malaysia, Chile, Mexico, Peru, Vietnam and others, and require stringent patent protection.&lt;/p&gt;&lt;p align=&quot;justify&quot;&gt;The companies and their supporters, however, argue strongly that without the financial reward that long-lasting patents offer, they will not have incentives to develop new medicines. They also threaten to boycott countries that will not allow them a monopoly on their own drugs.&lt;/p&gt;&lt;p align=&quot;justify&quot;&gt;No one thinks there are any simple solutions.&lt;/p&gt;&#039;
$lang = &#039;English&#039;
$SITE_URL = &#039;https://im4change.in/&#039;
$site_title = &#039;im4change&#039;
$adminprix = &#039;admin&#039;</pre><pre class="stack-trace">include - APP/Template/Layout/printlayout.ctp, line 8
Cake\View\View::_evaluate() - CORE/src/View/View.php, line 1413
Cake\View\View::_render() - CORE/src/View/View.php, line 1374
Cake\View\View::renderLayout() - CORE/src/View/View.php, line 927
Cake\View\View::render() - CORE/src/View/View.php, line 885
Cake\Controller\Controller::render() - CORE/src/Controller/Controller.php, line 791
Cake\Http\ActionDispatcher::_invoke() - CORE/src/Http/ActionDispatcher.php, line 126
Cake\Http\ActionDispatcher::dispatch() - CORE/src/Http/ActionDispatcher.php, line 94
Cake\Http\BaseApplication::__invoke() - CORE/src/Http/BaseApplication.php, line 235
Cake\Http\Runner::__invoke() - CORE/src/Http/Runner.php, line 65
Cake\Routing\Middleware\RoutingMiddleware::__invoke() - CORE/src/Routing/Middleware/RoutingMiddleware.php, line 162
Cake\Http\Runner::__invoke() - CORE/src/Http/Runner.php, line 65
Cake\Routing\Middleware\AssetMiddleware::__invoke() - CORE/src/Routing/Middleware/AssetMiddleware.php, line 88
Cake\Http\Runner::__invoke() - CORE/src/Http/Runner.php, line 65
Cake\Error\Middleware\ErrorHandlerMiddleware::__invoke() - CORE/src/Error/Middleware/ErrorHandlerMiddleware.php, line 96
Cake\Http\Runner::__invoke() - CORE/src/Http/Runner.php, line 65
Cake\Http\Runner::run() - CORE/src/Http/Runner.php, line 51</pre></div></pre>latest-news-updates/novartis-patent-ruling-a-victory-in-battle-for-affordable-medicines-sarah-boseley-20308.html"/>
    <meta http-equiv="Content-Type" content="text/html; charset=utf-8"/>
    <link href="https://im4change.in/css/control.css" rel="stylesheet" type="text/css"
          media="all"/>
    <title>LATEST NEWS UPDATES | Novartis patent ruling a victory in battle for affordable medicines-Sarah Boseley | Im4change.org</title>
    <meta name="description" content="
-The Guardian



Had Novartis won, it would have set a precedent for patenting of other medicines in India, delaying their reaching the poor


&nbsp;


The battle for affordable, life-saving medicines for poor countries was once waged on first-world city streets with banners and..."/>
    <script src="https://im4change.in/js/jquery-1.10.2.js"></script>
    <script type="text/javascript" src="https://im4change.in/js/jquery-migrate.min.js"></script>
    <script language="javascript" type="text/javascript">

        $(document).ready(function () {
            var img = $("img")[0]; // Get my img elem
            var pic_real_width, pic_real_height;
            $("<img/>") // Make in memory copy of image to avoid css issues
                .attr("src", $(img).attr("src"))
                .load(function () {
                    pic_real_width = this.width;   // Note: $(this).width() will not
                    pic_real_height = this.height; // work for in memory images.
                });
        });
    </script>
    <style type="text/css">
        @media screen {
            div.divFooter {
                display: block;
            }
        }

        @media print {
            .printbutton {
                display: none !important;
            }
        }
    </style>
</head>
<body>
<table cellpadding="0" cellspacing="0" border="0" width="98%" align="center">
    <tr>
        <td class="top_bg">
            <div class="divFooter">
                <img src="https://im4change.in/images/logo1.jpg" height="59" border="0"
                     alt="Resource centre on India's rural distress" style="padding-top:14px;"/>
            </div>

        </td>
    </tr>
    <tr>
        <td id="topspace">&nbsp;</td>
    </tr>

    <tr id="topspace">
        <td>&nbsp;</td>
    </tr>
    <tr>
        <td height="50" style="border-bottom:1px solid #000; padding-top:10px;" class="printbutton">
            <form><input type="button" value=" Print this page "
                         onclick="window.print();return false;"/></form>
        </td>
    </tr>

    <tr>
        <td width="100%">
            <h1 class="news_headlines" style="font-style:normal">
                <strong>Novartis patent ruling a victory in battle for affordable medicines-Sarah Boseley</strong></h1>
        </td>
    </tr>
    <tr>
        <td width="100%" style="font-family:Arial, 'Segoe Script', 'Segoe UI', sans-serif, serif"><font size="3">
                <div align="justify">-The Guardian</div><p align="justify"><br /><em>Had Novartis won, it would have set a precedent for patenting of other medicines in India, delaying their reaching the poor</em></p><p align="justify">&nbsp;</p><p align="justify">The battle for affordable, life-saving medicines for poor countries was once waged on first-world city streets with banners and placards. But for some years now it has been a long-hard legal slog in offices and courtrooms.</p><p align="justify">A decade or so ago, it was mostly about access to Aids drugs. Firms that made the drugs at prices too high for all but citizens of the rich world were shamed and left on the back foot by campaigners in the US and Europe.</p><p align="justify">The activists won some famous victories, breaking the patent stranglehold of the big firms and enabling the sale of cheap generic copies. Millions of people with HIV are alive and leading normal lives in poor countries as a result.</p><p align="justify">The multinational drug companies, however, have been working hard to prevent further erosion of their profits by generic, copycat manufacturers whom they once openly called pirates.</p><p align="justify">The companies, with support from the US and European governments which want a profitable drug industry, they have worked to tighten patent protection for new drugs through national laws and trade agreements. India has been the main focus in its historical role as the pharmacy of the developing world.</p><p align="justify">Under the World Trade Organisation's trade-related intellectual property rights (Trips) rules, India agreed to bring in patents for drugs in 2005. Drugs without patent protection before that date can still be copied and sold cheaply to developing countries by generics companies.</p><p align="justify">Novartis began seeking patent protection for its cancer drug Glivec as soon as the law came into force, but as the drug was already on the market the Swiss firm could not make a standard application. Instead, it sought a patent for a slightly altered version that it said was easier for patients to absorb. Novartis argued that this was innovation under Indian law and deserving of a patent.</p><p align="justify">The stakes were high. Glivec costs around &pound;1,700 a month. Indian generic copies cost around &pound;115.</p><p align="justify">Campaigners, already concerned that the Indian patent law would delay important new medicines reaching the poor, could see that if Novartis won its legal case, the &quot;evergreening&quot; of drugs by other companies would become routine. Patents usually expire after 20 years, meaning it could be decades more before prices would drop.</p><p align="justify">&quot;Had the Novartis case been successful, it definitely would have extended massively the ability to patent other medicines within India,&quot; said Jennifer Cohn, the medical director for M&eacute;decins Sans Fronti&egrave;res' access campaign.</p><p align="justify">It is an important victory, say the campaigners, but they still feel embattled. New classes of HIV drugs are being patented now in India and will not reach Africa for many years as a result, Cohn said. The same is true of new tuberculosis and hepatitis C drugs.</p><p align="justify">Campaigners also worry about trade agreements such as the Trans-Pacific Partnership, which is being negotiated between Australia, Canada, the US, Malaysia, Chile, Mexico, Peru, Vietnam and others, and require stringent patent protection.</p><p align="justify">The companies and their supporters, however, argue strongly that without the financial reward that long-lasting patents offer, they will not have incentives to develop new medicines. They also threaten to boycott countries that will not allow them a monopoly on their own drugs.</p><p align="justify">No one thinks there are any simple solutions.</p>               </font>
        </td>
    </tr>
    <tr>
        <td>&nbsp;</td>
    </tr>

    <tr>
        <td height="50" style="border-top:1px solid #000; border-bottom:1px solid #000;padding-top:10px;">
            <form><input type="button" value=" Print this page "
                         onclick="window.print();return false;"/></form>
        </td>
    </tr>
</table></body>
</html>'

}
$cookies = []
$values = [
	(int) 0 => 'text/html; charset=UTF-8'
]
$name = 'Content-Type'
$first = true
$value = 'text/html; charset=UTF-8'
header - [internal], line ??
Cake\Http\ResponseEmitter::emitHeaders() - CORE/src/Http/ResponseEmitter.php, line 181
Cake\Http\ResponseEmitter::emit() - CORE/src/Http/ResponseEmitter.php, line 55
Cake\Http\Server::emit() - CORE/src/Http/Server.php, line 141
[main] - ROOT/webroot/index.php, line 39

<head>

    <link rel="canonical" href="<?php echo Configure::read('SITE_URL'); ?><?php echo $urlPrefix;?><?php echo $article_current->category->slug; ?>/<?php echo $article_current->seo_url; ?>.html"/>

    <meta http-equiv="Content-Type" content="text/html; charset=utf-8"/>

$viewFile = '/home/brlfuser/public_html/src/Template/Layout/printlayout.ctp'
$dataForView = [
	'article_current' => object(App\Model\Entity\Article) {

		'id' => (int) 20167,
		'title' => 'Novartis patent ruling a victory in battle for affordable medicines-Sarah Boseley',
		'subheading' => '',
		'description' => '<div align="justify">
-The Guardian
</div>
<p align="justify">
<br />
<em>Had Novartis won, it would have set a precedent for patenting of other medicines in India, delaying their reaching the poor</em>
</p>
<p align="justify">
&nbsp;
</p>
<p align="justify">
The battle for affordable, life-saving medicines for poor countries was once waged on first-world city streets with banners and placards. But for some years now it has been a long-hard legal slog in offices and courtrooms.
</p>
<p align="justify">
A decade or so ago, it was mostly about access to Aids drugs. Firms that made the drugs at prices too high for all but citizens of the rich world were shamed and left on the back foot by campaigners in the US and Europe.
</p>
<p align="justify">
The activists won some famous victories, breaking the patent stranglehold of the big firms and enabling the sale of cheap generic copies. Millions of people with HIV are alive and leading normal lives in poor countries as a result.
</p>
<p align="justify">
The multinational drug companies, however, have been working hard to prevent further erosion of their profits by generic, copycat manufacturers whom they once openly called pirates.
</p>
<p align="justify">
The companies, with support from the US and European governments which want a profitable drug industry, they have worked to tighten patent protection for new drugs through national laws and trade agreements. India has been the main focus in its historical role as the pharmacy of the developing world.
</p>
<p align="justify">
Under the World Trade Organisation's trade-related intellectual property rights (Trips) rules, India agreed to bring in patents for drugs in 2005. Drugs without patent protection before that date can still be copied and sold cheaply to developing countries by generics companies.
</p>
<p align="justify">
Novartis began seeking patent protection for its cancer drug Glivec as soon as the law came into force, but as the drug was already on the market the Swiss firm could not make a standard application. Instead, it sought a patent for a slightly altered version that it said was easier for patients to absorb. Novartis argued that this was innovation under Indian law and deserving of a patent.
</p>
<p align="justify">
The stakes were high. Glivec costs around &pound;1,700 a month. Indian generic copies cost around &pound;115.
</p>
<p align="justify">
Campaigners, already concerned that the Indian patent law would delay important new medicines reaching the poor, could see that if Novartis won its legal case, the &quot;evergreening&quot; of drugs by other companies would become routine. Patents usually expire after 20 years, meaning it could be decades more before prices would drop.
</p>
<p align="justify">
&quot;Had the Novartis case been successful, it definitely would have extended massively the ability to patent other medicines within India,&quot; said Jennifer Cohn, the medical director for M&eacute;decins Sans Fronti&egrave;res' access campaign.
</p>
<p align="justify">
It is an important victory, say the campaigners, but they still feel embattled. New classes of HIV drugs are being patented now in India and will not reach Africa for many years as a result, Cohn said. The same is true of new tuberculosis and hepatitis C drugs.
</p>
<p align="justify">
Campaigners also worry about trade agreements such as the Trans-Pacific Partnership, which is being negotiated between Australia, Canada, the US, Malaysia, Chile, Mexico, Peru, Vietnam and others, and require stringent patent protection.
</p>
<p align="justify">
The companies and their supporters, however, argue strongly that without the financial reward that long-lasting patents offer, they will not have incentives to develop new medicines. They also threaten to boycott countries that will not allow them a monopoly on their own drugs.
</p>
<p align="justify">
No one thinks there are any simple solutions.
</p>',
		'credit_writer' => 'The Guardian, 1 April, 2013, http://www.guardian.co.uk/world/2013/apr/01/novartis-patent-ruling-affordable-medicines',
		'article_img' => '',
		'article_img_thumb' => '',
		'status' => (int) 1,
		'show_on_home' => (int) 1,
		'lang' => 'EN',
		'category_id' => (int) 16,
		'tag_keyword' => '',
		'seo_url' => 'novartis-patent-ruling-a-victory-in-battle-for-affordable-medicines-sarah-boseley-20308',
		'meta_title' => null,
		'meta_keywords' => null,
		'meta_description' => null,
		'noindex' => (int) 0,
		'publish_date' => object(Cake\I18n\FrozenDate) {},
		'most_visit_section_id' => null,
		'article_big_img' => null,
		'liveid' => (int) 20308,
		'created' => object(Cake\I18n\FrozenTime) {},
		'modified' => object(Cake\I18n\FrozenTime) {},
		'edate' => '',
		'tags' => [
			[maximum depth reached]
		],
		'category' => object(App\Model\Entity\Category) {},
		'[new]' => false,
		'[accessible]' => [
			[maximum depth reached]
		],
		'[dirty]' => [[maximum depth reached]],
		'[original]' => [[maximum depth reached]],
		'[virtual]' => [[maximum depth reached]],
		'[hasErrors]' => false,
		'[errors]' => [[maximum depth reached]],
		'[invalid]' => [[maximum depth reached]],
		'[repository]' => 'Articles'
	
	},
	'articleid' => (int) 20167,
	'metaTitle' => 'LATEST NEWS UPDATES | Novartis patent ruling a victory in battle for affordable medicines-Sarah Boseley',
	'metaKeywords' => 'novartis,generic drugs,patents,medicines',
	'metaDesc' => '
-The Guardian



Had Novartis won, it would have set a precedent for patenting of other medicines in India, delaying their reaching the poor


&nbsp;


The battle for affordable, life-saving medicines for poor countries was once waged on first-world city streets with banners and...',
	'disp' => '<div align="justify">-The Guardian</div><p align="justify"><br /><em>Had Novartis won, it would have set a precedent for patenting of other medicines in India, delaying their reaching the poor</em></p><p align="justify">&nbsp;</p><p align="justify">The battle for affordable, life-saving medicines for poor countries was once waged on first-world city streets with banners and placards. But for some years now it has been a long-hard legal slog in offices and courtrooms.</p><p align="justify">A decade or so ago, it was mostly about access to Aids drugs. Firms that made the drugs at prices too high for all but citizens of the rich world were shamed and left on the back foot by campaigners in the US and Europe.</p><p align="justify">The activists won some famous victories, breaking the patent stranglehold of the big firms and enabling the sale of cheap generic copies. Millions of people with HIV are alive and leading normal lives in poor countries as a result.</p><p align="justify">The multinational drug companies, however, have been working hard to prevent further erosion of their profits by generic, copycat manufacturers whom they once openly called pirates.</p><p align="justify">The companies, with support from the US and European governments which want a profitable drug industry, they have worked to tighten patent protection for new drugs through national laws and trade agreements. India has been the main focus in its historical role as the pharmacy of the developing world.</p><p align="justify">Under the World Trade Organisation's trade-related intellectual property rights (Trips) rules, India agreed to bring in patents for drugs in 2005. Drugs without patent protection before that date can still be copied and sold cheaply to developing countries by generics companies.</p><p align="justify">Novartis began seeking patent protection for its cancer drug Glivec as soon as the law came into force, but as the drug was already on the market the Swiss firm could not make a standard application. Instead, it sought a patent for a slightly altered version that it said was easier for patients to absorb. Novartis argued that this was innovation under Indian law and deserving of a patent.</p><p align="justify">The stakes were high. Glivec costs around &pound;1,700 a month. Indian generic copies cost around &pound;115.</p><p align="justify">Campaigners, already concerned that the Indian patent law would delay important new medicines reaching the poor, could see that if Novartis won its legal case, the &quot;evergreening&quot; of drugs by other companies would become routine. Patents usually expire after 20 years, meaning it could be decades more before prices would drop.</p><p align="justify">&quot;Had the Novartis case been successful, it definitely would have extended massively the ability to patent other medicines within India,&quot; said Jennifer Cohn, the medical director for M&eacute;decins Sans Fronti&egrave;res' access campaign.</p><p align="justify">It is an important victory, say the campaigners, but they still feel embattled. New classes of HIV drugs are being patented now in India and will not reach Africa for many years as a result, Cohn said. The same is true of new tuberculosis and hepatitis C drugs.</p><p align="justify">Campaigners also worry about trade agreements such as the Trans-Pacific Partnership, which is being negotiated between Australia, Canada, the US, Malaysia, Chile, Mexico, Peru, Vietnam and others, and require stringent patent protection.</p><p align="justify">The companies and their supporters, however, argue strongly that without the financial reward that long-lasting patents offer, they will not have incentives to develop new medicines. They also threaten to boycott countries that will not allow them a monopoly on their own drugs.</p><p align="justify">No one thinks there are any simple solutions.</p>',
	'lang' => 'English',
	'SITE_URL' => 'https://im4change.in/',
	'site_title' => 'im4change',
	'adminprix' => 'admin'
]
$article_current = object(App\Model\Entity\Article) {

	'id' => (int) 20167,
	'title' => 'Novartis patent ruling a victory in battle for affordable medicines-Sarah Boseley',
	'subheading' => '',
	'description' => '<div align="justify">
-The Guardian
</div>
<p align="justify">
<br />
<em>Had Novartis won, it would have set a precedent for patenting of other medicines in India, delaying their reaching the poor</em>
</p>
<p align="justify">
&nbsp;
</p>
<p align="justify">
The battle for affordable, life-saving medicines for poor countries was once waged on first-world city streets with banners and placards. But for some years now it has been a long-hard legal slog in offices and courtrooms.
</p>
<p align="justify">
A decade or so ago, it was mostly about access to Aids drugs. Firms that made the drugs at prices too high for all but citizens of the rich world were shamed and left on the back foot by campaigners in the US and Europe.
</p>
<p align="justify">
The activists won some famous victories, breaking the patent stranglehold of the big firms and enabling the sale of cheap generic copies. Millions of people with HIV are alive and leading normal lives in poor countries as a result.
</p>
<p align="justify">
The multinational drug companies, however, have been working hard to prevent further erosion of their profits by generic, copycat manufacturers whom they once openly called pirates.
</p>
<p align="justify">
The companies, with support from the US and European governments which want a profitable drug industry, they have worked to tighten patent protection for new drugs through national laws and trade agreements. India has been the main focus in its historical role as the pharmacy of the developing world.
</p>
<p align="justify">
Under the World Trade Organisation's trade-related intellectual property rights (Trips) rules, India agreed to bring in patents for drugs in 2005. Drugs without patent protection before that date can still be copied and sold cheaply to developing countries by generics companies.
</p>
<p align="justify">
Novartis began seeking patent protection for its cancer drug Glivec as soon as the law came into force, but as the drug was already on the market the Swiss firm could not make a standard application. Instead, it sought a patent for a slightly altered version that it said was easier for patients to absorb. Novartis argued that this was innovation under Indian law and deserving of a patent.
</p>
<p align="justify">
The stakes were high. Glivec costs around &pound;1,700 a month. Indian generic copies cost around &pound;115.
</p>
<p align="justify">
Campaigners, already concerned that the Indian patent law would delay important new medicines reaching the poor, could see that if Novartis won its legal case, the &quot;evergreening&quot; of drugs by other companies would become routine. Patents usually expire after 20 years, meaning it could be decades more before prices would drop.
</p>
<p align="justify">
&quot;Had the Novartis case been successful, it definitely would have extended massively the ability to patent other medicines within India,&quot; said Jennifer Cohn, the medical director for M&eacute;decins Sans Fronti&egrave;res' access campaign.
</p>
<p align="justify">
It is an important victory, say the campaigners, but they still feel embattled. New classes of HIV drugs are being patented now in India and will not reach Africa for many years as a result, Cohn said. The same is true of new tuberculosis and hepatitis C drugs.
</p>
<p align="justify">
Campaigners also worry about trade agreements such as the Trans-Pacific Partnership, which is being negotiated between Australia, Canada, the US, Malaysia, Chile, Mexico, Peru, Vietnam and others, and require stringent patent protection.
</p>
<p align="justify">
The companies and their supporters, however, argue strongly that without the financial reward that long-lasting patents offer, they will not have incentives to develop new medicines. They also threaten to boycott countries that will not allow them a monopoly on their own drugs.
</p>
<p align="justify">
No one thinks there are any simple solutions.
</p>',
	'credit_writer' => 'The Guardian, 1 April, 2013, http://www.guardian.co.uk/world/2013/apr/01/novartis-patent-ruling-affordable-medicines',
	'article_img' => '',
	'article_img_thumb' => '',
	'status' => (int) 1,
	'show_on_home' => (int) 1,
	'lang' => 'EN',
	'category_id' => (int) 16,
	'tag_keyword' => '',
	'seo_url' => 'novartis-patent-ruling-a-victory-in-battle-for-affordable-medicines-sarah-boseley-20308',
	'meta_title' => null,
	'meta_keywords' => null,
	'meta_description' => null,
	'noindex' => (int) 0,
	'publish_date' => object(Cake\I18n\FrozenDate) {},
	'most_visit_section_id' => null,
	'article_big_img' => null,
	'liveid' => (int) 20308,
	'created' => object(Cake\I18n\FrozenTime) {},
	'modified' => object(Cake\I18n\FrozenTime) {},
	'edate' => '',
	'tags' => [
		(int) 0 => object(Cake\ORM\Entity) {},
		(int) 1 => object(Cake\ORM\Entity) {},
		(int) 2 => object(Cake\ORM\Entity) {},
		(int) 3 => object(Cake\ORM\Entity) {}
	],
	'category' => object(App\Model\Entity\Category) {},
	'[new]' => false,
	'[accessible]' => [
		'*' => true,
		'id' => false
	],
	'[dirty]' => [],
	'[original]' => [],
	'[virtual]' => [],
	'[hasErrors]' => false,
	'[errors]' => [],
	'[invalid]' => [],
	'[repository]' => 'Articles'

}
$articleid = (int) 20167
$metaTitle = 'LATEST NEWS UPDATES | Novartis patent ruling a victory in battle for affordable medicines-Sarah Boseley'
$metaKeywords = 'novartis,generic drugs,patents,medicines'
$metaDesc = '
-The Guardian



Had Novartis won, it would have set a precedent for patenting of other medicines in India, delaying their reaching the poor


&nbsp;


The battle for affordable, life-saving medicines for poor countries was once waged on first-world city streets with banners and...'
$disp = '<div align="justify">-The Guardian</div><p align="justify"><br /><em>Had Novartis won, it would have set a precedent for patenting of other medicines in India, delaying their reaching the poor</em></p><p align="justify">&nbsp;</p><p align="justify">The battle for affordable, life-saving medicines for poor countries was once waged on first-world city streets with banners and placards. But for some years now it has been a long-hard legal slog in offices and courtrooms.</p><p align="justify">A decade or so ago, it was mostly about access to Aids drugs. Firms that made the drugs at prices too high for all but citizens of the rich world were shamed and left on the back foot by campaigners in the US and Europe.</p><p align="justify">The activists won some famous victories, breaking the patent stranglehold of the big firms and enabling the sale of cheap generic copies. Millions of people with HIV are alive and leading normal lives in poor countries as a result.</p><p align="justify">The multinational drug companies, however, have been working hard to prevent further erosion of their profits by generic, copycat manufacturers whom they once openly called pirates.</p><p align="justify">The companies, with support from the US and European governments which want a profitable drug industry, they have worked to tighten patent protection for new drugs through national laws and trade agreements. India has been the main focus in its historical role as the pharmacy of the developing world.</p><p align="justify">Under the World Trade Organisation's trade-related intellectual property rights (Trips) rules, India agreed to bring in patents for drugs in 2005. Drugs without patent protection before that date can still be copied and sold cheaply to developing countries by generics companies.</p><p align="justify">Novartis began seeking patent protection for its cancer drug Glivec as soon as the law came into force, but as the drug was already on the market the Swiss firm could not make a standard application. Instead, it sought a patent for a slightly altered version that it said was easier for patients to absorb. Novartis argued that this was innovation under Indian law and deserving of a patent.</p><p align="justify">The stakes were high. Glivec costs around &pound;1,700 a month. Indian generic copies cost around &pound;115.</p><p align="justify">Campaigners, already concerned that the Indian patent law would delay important new medicines reaching the poor, could see that if Novartis won its legal case, the &quot;evergreening&quot; of drugs by other companies would become routine. Patents usually expire after 20 years, meaning it could be decades more before prices would drop.</p><p align="justify">&quot;Had the Novartis case been successful, it definitely would have extended massively the ability to patent other medicines within India,&quot; said Jennifer Cohn, the medical director for M&eacute;decins Sans Fronti&egrave;res' access campaign.</p><p align="justify">It is an important victory, say the campaigners, but they still feel embattled. New classes of HIV drugs are being patented now in India and will not reach Africa for many years as a result, Cohn said. The same is true of new tuberculosis and hepatitis C drugs.</p><p align="justify">Campaigners also worry about trade agreements such as the Trans-Pacific Partnership, which is being negotiated between Australia, Canada, the US, Malaysia, Chile, Mexico, Peru, Vietnam and others, and require stringent patent protection.</p><p align="justify">The companies and their supporters, however, argue strongly that without the financial reward that long-lasting patents offer, they will not have incentives to develop new medicines. They also threaten to boycott countries that will not allow them a monopoly on their own drugs.</p><p align="justify">No one thinks there are any simple solutions.</p>'
$lang = 'English'
$SITE_URL = 'https://im4change.in/'
$site_title = 'im4change'
$adminprix = 'admin'

include - APP/Template/Layout/printlayout.ctp, line 8
Cake\View\View::_evaluate() - CORE/src/View/View.php, line 1413
Cake\View\View::_render() - CORE/src/View/View.php, line 1374
Cake\View\View::renderLayout() - CORE/src/View/View.php, line 927
Cake\View\View::render() - CORE/src/View/View.php, line 885
Cake\Controller\Controller::render() - CORE/src/Controller/Controller.php, line 791
Cake\Http\ActionDispatcher::_invoke() - CORE/src/Http/ActionDispatcher.php, line 126
Cake\Http\ActionDispatcher::dispatch() - CORE/src/Http/ActionDispatcher.php, line 94
Cake\Http\BaseApplication::__invoke() - CORE/src/Http/BaseApplication.php, line 235
Cake\Http\Runner::__invoke() - CORE/src/Http/Runner.php, line 65
Cake\Routing\Middleware\RoutingMiddleware::__invoke() - CORE/src/Routing/Middleware/RoutingMiddleware.php, line 162
Cake\Http\Runner::__invoke() - CORE/src/Http/Runner.php, line 65
Cake\Routing\Middleware\AssetMiddleware::__invoke() - CORE/src/Routing/Middleware/AssetMiddleware.php, line 88
Cake\Http\Runner::__invoke() - CORE/src/Http/Runner.php, line 65
Cake\Error\Middleware\ErrorHandlerMiddleware::__invoke() - CORE/src/Error/Middleware/ErrorHandlerMiddleware.php, line 96
Cake\Http\Runner::__invoke() - CORE/src/Http/Runner.php, line 65
Cake\Http\Runner::run() - CORE/src/Http/Runner.php, line 51

Novartis patent ruling a victory in battle for affordable medicines-Sarah Boseley

-The Guardian Had Novartis won, it would have set a precedent for patenting of other medicines in India, delaying their reaching the poor   The battle for affordable, life-saving medicines for poor countries was once waged on first-world city streets with banners and placards. But for some years now it has been a long-hard legal slog in offices and courtrooms. A decade or so ago, it was mostly about access to Aids drugs. Firms that made the drugs at prices too high for all but citizens of the rich world were shamed and left on the back foot by campaigners in the US and Europe. The activists won some famous victories, breaking the patent stranglehold of the big firms and enabling the sale of cheap generic copies. Millions of people with HIV are alive and leading normal lives in poor countries as a result. The multinational drug companies, however, have been working hard to prevent further erosion of their profits by generic, copycat manufacturers whom they once openly called pirates. The companies, with support from the US and European governments which want a profitable drug industry, they have worked to tighten patent protection for new drugs through national laws and trade agreements. India has been the main focus in its historical role as the pharmacy of the developing world. Under the World Trade Organisation's trade-related intellectual property rights (Trips) rules, India agreed to bring in patents for drugs in 2005. Drugs without patent protection before that date can still be copied and sold cheaply to developing countries by generics companies. Novartis began seeking patent protection for its cancer drug Glivec as soon as the law came into force, but as the drug was already on the market the Swiss firm could not make a standard application. Instead, it sought a patent for a slightly altered version that it said was easier for patients to absorb. Novartis argued that this was innovation under Indian law and deserving of a patent. The stakes were high. Glivec costs around £1,700 a month. Indian generic copies cost around £115. Campaigners, already concerned that the Indian patent law would delay important new medicines reaching the poor, could see that if Novartis won its legal case, the "evergreening" of drugs by other companies would become routine. Patents usually expire after 20 years, meaning it could be decades more before prices would drop. "Had the Novartis case been successful, it definitely would have extended massively the ability to patent other medicines within India," said Jennifer Cohn, the medical director for Médecins Sans Frontières' access campaign. It is an important victory, say the campaigners, but they still feel embattled. New classes of HIV drugs are being patented now in India and will not reach Africa for many years as a result, Cohn said. The same is true of new tuberculosis and hepatitis C drugs. Campaigners also worry about trade agreements such as the Trans-Pacific Partnership, which is being negotiated between Australia, Canada, the US, Malaysia, Chile, Mexico, Peru, Vietnam and others, and require stringent patent protection. The companies and their supporters, however, argue strongly that without the financial reward that long-lasting patents offer, they will not have incentives to develop new medicines. They also threaten to boycott countries that will not allow them a monopoly on their own drugs. No one thinks there are any simple solutions.